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ABSTRACT 
 
Background: The rising rates of Type 2 diabetes (T2DM) around the world have 
serious economic and health implications, often related to the complications of 
the condition. One such problem is the impact of diabetes on cognitive function. 
In older adults with T2DM, there is an established relationship between diabetes 
and cognitive impairment in people with and without dementia. Emerging 
evidence suggests this may also be the case for younger adults, as the 
occurrence of cognitive deficits in people with T2DM is related to the severity and 
duration of the condition. In some parts of the world, T2DM has become the most 
common diabetes phenotype in children. Therefore, exploring the cognitive 
function of younger adults with T2DM is important, to understand the 
pathogenesis and sequelae of the condition across the lifespan. 
Aims: To investigate if younger adults with T2DM show signs of cognitive 
impairment, and how this relates to diabetes-related health indicators.  
Method: Ten people with T2DM were recruited from a diabetes clinic in London, 
and completed a battery of cognitive tests assessing processing speed, attention, 
executive function, learning and memory.  Estimates of optimal (premorbid) ability 
were also derived.  Clinically relevant markers for diabetes were recorded, 
including Hba1c and lipid profiles.  
Results: Scores on cognitive tests suggested deficits in attention and processing 
speed, but executive function was a relative strength. Scores were not declined 
relative to one measure of optimal ability across the group. Health markers 
related to diabetes were correlated with several cognitive domains, although not 
consistently: total cholesterol levels showed the strongest associations, and not 
always in the direction anticipated. 
Conclusions: Due to the small sample size, any profiles and associations should 
be treated cautiously. Further research in this area is needed, and cognitive 
impairment in people with T2DM should be attended to routinely in clinical 
services. 
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1. INTRODUCTION, AIMS & JUSTIFICATION 
 
 
1.1 Literature Search 
 
The search strategy used to inform the literature presented here was undertaken 
in four stages. The first was a scoping search, by finding existing reviews and 
becoming familiar with which databases would be included in the final search.  
 
Secondly, key search terms for each database were defined, and further terms 
were sought using pearl-growing, and this formulated a search strategy.  
 
Third, the database search was performed, using PubMed, PsycInfo, Science 
Direct, Scopus and Google Scholar, employing free text and thesaurus searching 
methods (where thesaurus was permitted).  
 
Finally, a bibliography search was conducted by looking at reference lists of 
papers, key authors and within highly cited or key articles for additional 
references.  
 
1.2 What is Diabetes? 
 
Diabetes Mellitus (DM) is a metabolic syndrome in humans that is characterised 
by chronic hyperglycaemia, or high levels of glucose in the blood, that the body is 
unable to use. In order to use glucose or blood glucose insulin is required, which 
is a hormone that regulates blood sugar. There are lots of different types of 
diabetes, but developing the condition is most likely due to one of two reasons: 
either the body does not produce insulin  - Type 1 Diabetes Mellitus (T1DM), or 
the insulin it produces is ineffective - Type 2 Diabetes Mellitus (T2DM). The ability 
to regulate glucose in the body is known as glycemic control. Once termed a 
disease of the West, T2DM is now a global issue and has been called the biggest 
health epidemic of this century (Tabish, 2007). Whilst it is treatable and 
accordingly is seen as a long-term condition, every five minutes, someone in the 
world dies from diabetes-related illness (International Diabetes Federation, 2015). 
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1.3 History of Diabetes 
 
The symptoms of diabetes were first mentioned in Egyptian manuscripts in 1500 
B.C., when it was observed that ants were attracted to the urine of people with an 
emaciating disease (MacCracken & Hoel, 1997). The condition did not come to 
have the name ‘diabetes’ until around 250 B.C. Diabetes, comes from the Greek 
word for a siphon, as the condition was characterised by liquid leaving the body 
in the form of excessive urination. The word ‘mellitus’ (honeyed) was added when 
a London physician in the late 18th century tasted the urine of his patients with 
diabetes, and noted that it was sweet (Tatersall, 2010). This was actually a re-
discovery as in India 400 B.C., the term ‘honeyed urine’ was first used. Although 
the link between diabetes and the pancreas was identified in the 1800s, the 
connection between diabetes and insulin was discovered later. In 1921, it was 
established after many years of speculation that an insulin deficiency was 
implicated in diabetes (Barnett & Krall, 2005).   
 
The subdivision of diabetes into different types was first recognised in the 1700s 
onwards, noting that leanness (T1DM) or obesity and later onset (T2DM) was 
commonly associated with the condition (Alberti, 2010). However, the diagnostic 
terms were established in the mid 60’s (World Health Organisation, 1964).  
 
1.4 Different types of diabetes 
 
Although there are several different types of diabetes, for the purpose of the 
thesis, I will be focusing on explaining the two most common types, T1DM and 
T2DM, in greater detail.  
 
1.4.1 T1DM  
T1DM is an autoimmune disorder that destroys insulin-producing beta cells in the 
pancreas, and people with the condition can also have insulin resistance (Alberti, 
2010). It typically develops in childhood or early adolescence, is normally 
diagnosed no later than 30 years old and, once diagnosed, people with T1DM 
require insulin to live. People with T1DM account for about 5-10% of those with a 
diabetes diagnosis (American Diabetes Association, 2008).  
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1.4.2 T2DM 
Historically, T2DM (referred interchangeably with diabetes from this point on) was 
known as the older adults’ disease. This was due in part to the higher incidence 
in the older population, estimated as one in four in some countries (Gambert & 
Pinkstaff, 2006). However, T2DM is now very common in middle-aged adults. It is 
the most common form of diabetes, with around 90-95% of people with diabetes 
having T2DM (American Diabetes Association, 2008). It is characterised by either 
not making enough insulin or the insulin generated being ineffective. Unlike 
T1DM, people with T2DM do not usually need insulin for survival, but as the 
condition progresses, people may require insulin to ensure they control their 
blood sugar effectively (Alberti, 2010).  
 
1.5 Diagnostic Criteria 
 
Typically, people who present with symptoms of diabetes such as thirst, polyuria 
(excessive urination), weight loss, or recurrent infections would be tested for 
diabetes. In the last 10 years, there have been three ways in which people 
around the world have been tested for diabetes by: casual, fasting, and oral 
glucose load. 
 
1.5.1.1 Casual glucose load: can be measured by a one-off measurement of 
blood glucose and a definite diagnosis would be given to someone with a blood 
plasma level greater than 11.1 mmol/L (200mg/dL) or 12.2 mmol/L (220mg/dL) in 
capillary plasma. Any values between 5.0-11.0 would be uncertain and may 
constitute ‘Prediabetes’ or Impaired Glucose Tolerance (IGT) (see below).  
 
1.5.1.2 Fasting glucose test (FGT): is a blood taken after fasting. It is usually 
done in the morning, as it requires patients not to have eaten or drunk anything 
for eight to 12 hours before testing. A plasma level of 7.0 mmol/L (126mg/dl and 
above) may indicate the presence of diabetes. A blood glucose level between 6.1 
and 6.9 mmol/L (between 11mg/dl and 125mg/dl) could indicate impaired fasting 
glucose (IFG).  
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1.5.1.3 Oral glucose tolerance testing (OGTT): was developed in the 19th century, 
but only became more common when blood testing became easier to conduct. It 
was recommended in the first diagnostic criteria defined by the World Health 
Organisation (1964), who stated that glycosuria – raised sugar in urine - was 
insufficient to confirm or rule out diabetes. Before the test, patients are asked to 
eat at least 250g carbohydrates for three days prior to testing, and to refrain from 
eating or drinking certain fluids, eight to 12 hours before testing. As part of the 
test, the patient will have their blood tested, then be given a glucose drink, and 
their blood will be tested again two hours later.  
 
1.5.1.4 ‘Borderline diabetes’ or ‘Prediabetes’: is a concept that has emerged 
since the late 1970s, where people without diabetes had blood plasma levels of 
glucose, which were higher than normal. The World Health Organisation (1980) 
named this Impaired Glucose Tolerance (IGT). Later, the concept of Impaired 
Fasting Glucose (IFG) was added, to indicate blood glucose that was high but 
below the threshold for a diabetes diagnosis. The presence of both IGT and IFT 
in a person, has led to the introduction of a label known as ‘prediabetes’, 
although not everyone affected will go on to develop diabetes. In this sense, the 
label is seen as less helpful and some relevant bodies prefer the term 
‘intermediate hypoglycaemia’ (World Health Organisation, 1999).  
 
1.5.2 Hba1c 
Although raised blood glucose has been a cornerstone in identifying different 
types of diabetes for over 100 years (Alberti, 2010), it has its problems with its 
accuracy. Hba1c, also know as glycated haemoglobin, measures glycaemic 
control over weeks, rather than at a specific moment in time. It gives a better 
indication than an oral or fasting glucose test that a person is hypoglycaemic, and 
with better accuracy (Alberti, 2010). However, it is expensive and its validity as a 
standardised measure was called into question, as there were variations in the 
methods used in laboratories. Recently, more widespread use of Hba1c as a 
diagnostic measure of diabetes has been recommended (American Diabetes 
Association, 2009). The World Health Organisation (2011) also followed suit, with 
a caveat that when Hba1c is used diagnostically that “there are no conditions 
present that preclude its measurement” (p.3). The diagnostic criteria for using 
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Hba1c is a cut off of 6.5% for diagnosing diabetes, but anything below this does 
not rule out diabetes diagnosed via glucose testing. 
 
1.5.3 Variation in diagnosis around the world  
As the implications of diabetes can be lifelong and difficult, it is important that 
diabetes is diagnosed correctly. However, as mentioned previously, the criteria 
that has been used for diabetes diagnosis has varied worldwide – in part due to 
availability of Hba1c testing. As such, when evaluating relevant studies of people 
with diabetes, the accepted diagnosis will either be using Hba1c or by casual, 
fasting or oral glucose testing.    
 
1.6 Epidemiology of Diabetes 
 
Using the above diagnostic criteria, in 2015, there were 2.8 million people in the 
UK and 415 million people worldwide with diabetes. By 2040, that is estimated to 
rise to 3.5 million people and 642 million respectively (International Diabetes 
Federation, 2015). Currently, those figures equate to 1 in 11 having diabetes, 
rising to one in 10 in less than 30 years time. The global cost of diabetes annually 
is estimated as $825 billion (NCD Risk Factor Collaboration, 2016), with 
approximately 12% of global health expenditure on diabetes. The healthcare cost 
of people with diabetes is calculated as around two to three times higher than a 
person without diabetes (International Diabetes Federation, 2015). The reason 
for this difference is partially explained by the rising cost of medication, but also 
the increase in numbers of people with diabetes and diabetic related 
complications.  
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1.7 Management of Diabetes 
 
As every person with diabetes is different, the management of the condition is 
done in various ways. However, in the UK there are several aspects of diabetes 
care that are standardised. According to the National Institute for Health and 
Care Excellence (2016b), as someone with T2DM, one should expect the 
following from your diabetes healthcare professional: 
 
• Advice about local support groups 
• The opportunity to attend a diabetes education group 
• Diet and lifestyle advice 
• An annual blood pressure check 
• Regular blood glucose check 
• Quarterly to bi-annual Hba1c check 
• Discussions about medication to control your blood glucose 
• Where necessary, discussions about insulin and how to inject properly 
• Explanations about hypoglycaemia or ‘hypos’, and the symptoms, risks 
and treatment 
• Exploring risk of cardiovascular disease now and in the future 
• Offering regular eye screening and foot checks 
• Checking other possible complications such as kidney disease or nerve 
problems 
 
As a result, the burden of diabetes is high and this is on several levels: to the 
individual in terms of health-related burden e.g. medication (Black et al., 2015), 
social burden – including the impact on the family and retaining gainful 
employment (Von Korff et al., 2005), and the associated economic impact of 
diabetes, both directly because of health expenditure and also the indirect cost, 
due to lack of productivity e.g. being unable to work (Ali, Weber, & Narayan, 
2015). As a result of these factors compromising a collective burden, there is 
interest worldwide to reduce the impact that diabetes has on multiple levels in 
society. 
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1.8 Complications of Diabetes 
 
As part of the global health agenda, diabetes is the most common of four non-
communicable diseases (NCD) (cannot be transmitted from person to person) 
that are focused on by world leaders due to the disability and premature death 
they cause. People with diabetes are at increased risk of developing 
complications if their blood glucose levels remain high. These complications can 
make diabetes more difficult to manage but can also cause life altering disabilities 
or even death. Whilst diabetes care is aimed at making sure that hyperglycaemia 
is avoided, a secondary aim of diabetes management is preventing damage to 
the human vascular tree of the body (Fowler, 2008) - including microvascular 
(small) and macrovascular (large) blood vessels.  
 
1.8.1 Microvascular complications 
 
1.8.1.1 Retinopathy: is an eye disease affecting the blood vessels, which can 
lead to vision loss or blindness. The cause of retinopathy in diabetes is 
consistently high blood glucose. Retinopathy can be at an advanced stage before 
symptoms are detected so regular eye screening is recommended for people with 
diabetes.  
 
1.8.1.2 Diabetic foot and nerve damage: can develop in people with diabetes 
because of reduced blood flow to the extremities, which causes nerve damage. 
The nerve damage occurs due to high blood glucose levels over time. The most 
common form of nerve damage in diabetes is peripheral neuropathy affecting the 
feet, but it can also affect other parts of the body such as the hands. The nerve 
damage causes pain, tingling and numbness, which can be problematic because 
symptoms in the feet can go undetected for some time, leading to infections, 
ulcers and sometimes amputation. Other complications from nerve damage 
include problems with urination, erectile dysfunction, vaginal dryness and loss of 
sensation, amongst other complaints.  
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1.8.2 Macrovascular complications 
 
1.8.2.1 Hypertension: is defined as high blood pressure which is considered to 
comprise a systolic pressure (the force at which your heart pumps blood around 
your body) of 140 or above and a diastolic pressure (the resistance to the blood 
flow in the vessels) of 90 or above e.g. 140/90 or higher. It affects between 67% 
and 71% of people with T2DM (Suh, Kim, Choi, Plauschinat, & Barone, 2009; 
Centers for Disease Control and Prevention, 2014). As such, hypertension is 
often seen as a condition that interacts with diabetes, and shares several 
underlying risk factors, including ethnicity, familial risk and lifestyle (Long & 
Dagogo-Jack, 2011). Whilst hypertension has been highlighted as a 
macrovascular complication, like diabetes, it can have implications on a 
microvascular level as well. Hypertension without diabetes is best managed by 
blood pressure monitoring, medication and lifestyle changes, such as a healthy 
diet and regular exercise, and reducing smoking, alcohol, salt and caffeine intake 
(National Institute for Health and Care Excellence, 2016c). Hypertension that is 
concurrent with diabetes is managed similarly, but focuses on medication, 
improved glucose and lipid control (National Institute for Health and Care 
Excellence, 2016b). 
  
1.8.2.2 Cardiovascular disease (CVD): refers to several conditions affecting the 
heart such as angina, myocardial infarction (MI or heart attack), congestive heart 
failure, peripheral artery disease and stroke. These conditions do not develop 
exclusively as a result of high blood glucose, but are also affected by 
dyslipidaemia (abnormal levels of lipids in the blood) and hypertension. CVD is 
the biggest risk factor for people with diabetes and they have a two to four fold 
risk of developing CVD across their lifetime compared to people without diabetes 
(Kannel, 1985), with men more likely than women to develop it (Kannel & McGee, 
1979). CVD is the leading cause of disability and death of people with diabetes. 
However, there are a number of factors that can mitigate this risk and research 
has focused on aspects of how someone comes to develop CVD.  
 
1.8.2.3 Dyslipidemia: is defined as an abnormal level of lipids in the blood. This 
could be indicated by a high level of low-density lipoprotein cholesterol (LDL) or a 
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low level of high-density lipoprotein cholesterol (HDL) in the blood. Both LDL and 
HDL are implicated in the development of CVD as the former seems to be 
atherogenic (it promotes the formation of fatty deposits in the arteries) while the 
latter is atheroprotective (it protects from atherosclerosis) where the arteries 
become blocked by fatty deposits (Viljoen & Wierzbecki, 2010). Dyslipidemia in 
diabetes is characterised as the pattern of having decreased HDL, increased LDL 
and triglycerides (TG) (fat in the blood), (Musunuru, 2010), and all three combine 
to be an independent risk factor of CVD (Manjunath, Rawal, Irani, & Madhu, 
2013).  
 
Targets for optimum lipid control in someone with diabetes should be total 
plasma cholesterol <4.5-mmol/L (~175 mg/dL) and LDL <2.5mmol/L 
(~100mg/dL), at least. Whilst no targets are set for HDL and TG, HDL 
concentrations in men <1.2mmol/L (~40mg/dL) and women <1.2mmol/L 
(~40mg/dL) and TG >1.7mmol/L (~150mg/dL) would be an indication of 
increased CVD risk (Graham et al., 2007).  
 
1.8.3 Metabolic Syndrome 
T2DM is connected with ‘metabolic syndrome’ – a set of cardiovascular risk 
factors, including hypertension, hyperinsulinemia (abnormal glucose tolerance), 
visceral abdominal adiposity, dyslipidaemia, and pro inflammatory states. These 
risk factors are inextricably linked and once combined in an individual, are 
sometimes indistinguishable as distinct conditions. Each condition that is present 
in a person exponentially increases their risk of developing chronic heart disease 
and mortality (Ali et al., 2015).  
 
1.9 Risk factors in developing diabetes 
 
1.9.1 Obesity and Overweight 
One of the most important and modifiable risk factors for developing T2DM is 
obesity. Obesity accounts for 80-85% of the overall risk for developing diabetes 
(Huner, 2015). Obesity is defined as an excess of adipose tissue or fat, to the 
extent that health may be impaired (World Health Organisation, 1999). This 
excess fat is of most concern when it is distributed in a specific place, such as the 
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abdomen. This central adiposity is seen as more serious than fat that is 
distributed more evenly around the body.  
 
In fact, the relationship between diabetes and overweight also indicates that 
abdominal fat distribution is an independent risk factor for developing diabetes 
(Ohlson et al., 1985). This is because the presence of excess body fat seems to 
promote insulin resistance and prevent insulin secretion, or it can produce a pro-
inflammatory chemical response that modulates insulin sensitivity (Shoelson, 
Herrero, & Naaz, 2007). It seems whichever mechanism body fat affects insulin, it 
is essential in metabolising glucose (Huner, 2015).  
 
1.9.2 Preventing diabetes and its complications 
Despite all these conditions being preventable, these complications have become 
so common that in the USA, only 14% of people with T2DM did not have a 
comorbid condition (Suh, Choi, Plauschinat, Kwon, & Baron, 2010).  Therefore, 
research has focused on the impact of diabetes, including understanding 
effective management, treatment and how to intervene earlier to minimise and 
reduce the complications of the condition (Hu, 2011; Lam & LeRoith, 2012). As 
mentioned previously, T2DM used to be more commonly associated with older 
adults.  Therefore, much of the research into the pathophysiology i.e. how it 
affects the body, have focused on diabetes in older populations.  
 
1.10 Older people with Diabetes 
 
Older people are at an increased risk of diabetes as aging is associated with the 
gradual loss of glycemic control (Resnick, Harris, Brock, & Harris, 2000). 
Approximately 1 in 4 people who are aged over 65 have diabetes in the United 
States (Centers for Disease Control and Prevention, 2014). Because of this 
prevalence, T2DM used to be referred to as the ‘older adults’ disease (Gambert & 
Pinkstaff, 2006). However, the prevalence of T2DM has been increasing around 
the world and across the lifespan, and this rise has been linked to higher rates of 
obesity, sedentary lifestyles and being overweight (Hu, 2011).  
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The link between aging and developing diabetes is thought to be more complex 
than originally thought.  Research indicates there is a connection between how 
Alzheimer’s Disease (Dementia Alzheimer’s Type or DAT) and diabetes both 
progress in the brain, to the extent that there have been calls to rename DAT 
‘Type 3 Diabetes’ (De la Monte & Wands, 2008). DAT can be considered akin to 
a metabolic condition, which shares many of the characteristics of diabetes: 
namely that insulin and IFG resistance and deficiency drive DAT, mimicking the 
development of diabetes (De la Monte & Tong, 2014). Furthermore, it has long 
been known that having diabetes is a risk factor for vascular dementia 
(MacKnight, Rockwood, Awalt, & McDowell, 2002). This would indicate that 
insulin not only has endocrine implications in the body, but that it has a significant 
impact on the brain and its functioning (Cholerton, Baker, & Craft, 2013). 
Therefore, another dimension that should be considered in diabetes is cognitive 
function. 
 
1.11 Cognitive Function  
 
Cognitive function is a term that refers to the ability to think, remember and 
process information. In diabetes, one way cognition may be affected is because 
the functioning of the brain relies on a healthy blood supply. As diabetes is 
characterised by higher blood glucose, the ‘blood quality’ may be compromised if 
the diabetes is not well controlled. 
 
We can measure the extent to which we are functioning cognitively in several 
ways, but most often this is measured by neuropsychological assessments. 
There are several domains that can be assessed in neuropsychology, but there 
are certain areas that are seen as more important to assess in people with 
conditions such as diabetes.  
 
1.11.1 Processing Speed  
Processing speed (PS) refers to our ability to attend to information flexibly and in 
a timely fashion, using scanning and sequencing visual information. As with 
attention, processing speed is a construct that can be observed operating on 
other domains but likewise is an essential skill in cognitive functioning. As 
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neurons have the highest energy demand and require constant delivery of 
glucose via the blood, the processing power is determined by this energy supply 
(Howarth, Gleeson, & Attwell, 2012). Research over the last 15 years into 
diabetes has shown that in terms of cognitive impairment, processing speed is 
most typically affected by the presence of T2DM (Stewart & Liolitsa, 1999; Awad, 
Gagnon, & Messier, 2004; Manschot et al., 2006), although there is some 
suggestion that vascular complications e.g. heart failure, or smoking status 
mediate this association (Arvanitakis, Wilson, Li, Aggarwal, & Bennet, 2006).  
 
1.11.2 Attention 
Attention is our ability to focus on information, as well as divide and sustain it, 
often involving mental manipulation and being impervious to distraction from 
external stimuli. There is no test that measures attention in itself but it is regarded 
as a building block for other cognitive skills, so it is a necessary thing to measure 
as a foundation for all cognitive skills (Hebben & Milberg, 2009). Some studies 
have indicated that attention can be compromised in people with T2DM 
(Manschot et al., 2006), although other more longitudinal research into the effects 
of diabetes on attention did not find a direct association between T2DM and 
attention (Degen, Toro, Schönknecht, Sattler, & Schröder, 2016). 
 
1.11.3 Executive Function 
Executive function (EF) is ability to take in information, hold it in mind and do 
something with it, and it is connected to self-control and regulation. EF also 
compromises other domains such as inhibition, regulation, working memory and 
switching between tasks. Meta-analyses assessing the impact of T2DM on EF in 
older or middle age populations have found EF significantly lower in people with 
diabetes compared to non-diabetic controls (Vincent & Hall, 2015). This 
relationship between EF and T2DM has been observed in both Eastern and 
Western populations that are 65 and older, but also that cognition overall was 
compromised compared to non-diabetic controls (Zhao et al., 2015).  
 
1.11.4 Memory 
Memory refers to our capacity to encode, store and retrieve information and is 
usually assessed both verbally and visually. Manschot et al. (2006) found that 
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alongside other cognitive domains, verbal memory was most impacted in people 
with diabetes compared to non-diabetic controls. A cross-sectional sample of 
older adults without dementia found that deficits in semantic memory (and 
processing speed) were also associated with the presence of diabetes 
(Arvanitakis et al., 2006). However, in other research using a control group, a 
significant difference was not found for memory once presence of hypertension 
was controlled for (Van Harten et al., 2007). More recently, research into which 
memory processes are affected by diabetes has shown that explicit memory (e.g. 
consciously remembering previous experiences) is most compromised in people 
with T2DM compared to cognitively normal older adults (Redondo, Beltrán-
Brotóns, Reales, & Ballesteros, 2015).  
 
1.12 Factors contributing to Cognitive Function 
 
1.12.1 Premorbid functioning 
Usually, information about a person’s cognitive function is not available before 
they develop a condition or an injury. Skills such as vocabulary and word reading 
correlate highly with general level of ability and are hypothesised to remain intact 
after an illness develops in some neurological conditions. Therefore, premorbid 
functioning estimates the optimal ability of someone before the onset of illness 
(Hebben & Milberg, 2009). In the context of diabetes, very little information is 
available in the literature about T2DM and premorbid functioning, One study that 
specified in the title that its focus was premorbid functioning did not use any 
measures to assess it (Wong, Scholey, & Howe, 2014), and others were small 
scale samples (N=<40) which found no differences between middle aged and 
older people with T2DM and a control group (Cosway, Strachan, Dougall, Frier, & 
Deary, 2001; Asimakopoulou, Hampson, & Morrish, 2002). Therefore, there is 
very little literature available about optimal ability and people with T2DM. 
 
1.12.2 Mood and Anxiety 
For all people with diabetes, it is estimated between 10-30% of those also have 
depression (Ali, Stone, Peters, Davies, & Khunti, 2006; Adriaanse & Pouwer, 
2016). However, age can make a difference, as older adults with diabetes are 
twice as likely to be depressed compared to those without diabetes (Munshi et al, 
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2006). Although depression is thought to be more common in people with 
diabetes (Fisher et al., 2008), having diabetes is associated with the development 
of other affective disorders, such as anxiety (Kruse, Schmitz, & Thefeld, 2003). 
Indeed, self-report research of people with diabetes has put the estimated 
prevalence of anxiety symptoms as double that of the general population (Collins, 
Corcoran, & Perry, 2009).  
 
Developing mental health problems whilst having diabetes has been linked to the 
treatment burden of the condition, both psychological and physical, as the 
treatment regime relies heavily on strict self-management. Experiencing 
comorbid depression and diabetes is also associated with higher use of health 
services and entails increased cost (Egede, Zheng, & Simpson, 2002). 
Furthermore, the relationship between depression and diabetes control is thought 
to be bi-directional, with one impacting the other in a vicious cycle (Adriaanse & 
Pouwer, 2016). Despite this understanding, the process of how they come to 
affect each other in neurological terms is yet to be disentangled. 
 
1.13 Correlates of Cognitive Function in Diabetes 
 
Whilst there is extensive research into how T2DM affects the brain, there are no 
definitive neurological areas that are always affected by it. This is most likely due 
to the fact that firstly, the pathophysiology of the condition is still not well 
understood in this context (Kodl & Seaquist, 2008); and secondly, it may be in 
part due to T2DM being a syndrome rather than an established set of symptoms 
that can vary widely from person to person. Therefore, it is useful to summarise 
what is understood by considering relevant clinical markers in diabetes and their 
potential relationship to cognition: 
 
1.13.1 Cognition and Hba1c 
As noted earlier, Hba1c is seen as the preferred measure of glycemic control. 
Over a period of nine years, a study of older adults found that higher levels of 
Hba1c were associated with worse cognitive function and overall decline (Yaffe et 
al., 2012). In a sample of over 4000 older adults, Zhong, Jin, Xu and Fu (2015) 
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found that the ratio of Hba1c to Glycated Albumin (GA) was negatively correlated 
with cognitive function in a non-diabetic population.  
 
Research into memory and diabetes in older adults has found that whilst diabetes 
can accelerate memory loss, a higher Hba1c in people without diabetes can also 
predict memory decline (Marden, Mayeda, Tchetgen, Kawachi, & Glymour, 
2017). However, despite the large sample size of nearly 9000 older adults, the 
test of memory selected – the Informant Questionnaire for Cognitive Decline - 
was not typically used in neuropsychology and therefore, cannot be compared to 
other tests in a meta analyses, nor directly to Western constructs of tests of 
memory e.g. Wechsler Memory Scale.  
 
As with much of the research in the area, the conclusions drawn rely on crude 
means of measuring cognition typically used by psychiatrists, such as the Mini 
Mental State Examination (MMSE) and the Montreal Cognitive Assessment 
(MoCA). Brief screenings for dementia such as the MMSE, are not widely 
considered as suitable to sensitively measure cognitive defects (Tombaugh & 
Mcintyre, 1992). It would seem there are some methodological issues with 
existing research into diabetes that are yet to be addressed. 
 
1.13.2 Cognition and hypertension 
As around 2/3 of people with T2DM also have hypertension (Suh et al., 2009), it 
has not always been easy to establish hypertension as an independent risk factor 
for cognitive decline. In a systematic review of evidence into hypertension, Van 
den Berg, Kloppenborg, Kessels, Kappelle, & Biessels (2009), found that high 
blood pressure was associated with a poorer cognitive performance in seven out 
of 11 cross-sectional studies and ten out of 13 studies. Interestingly, some 
studies also found an inverse U-relationship with low and high blood pressure 
impacting negatively on cognitive performance. According to the review, the 
domains affected by hypertension in order of most to least were memory, 
processing speed, attention and visuo-spatial construction. Language was seen 
as unaffected by hypertension in all studies included.  
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Although using medication to treat hypertension has been associated with 
improved cognitive function (Guo et al., 1999), a Cochrane review found that 
treating people for hypertension does not protect against cognitive impairment or 
dementia in later life (McGuinness, Todd, Passmore, & Bullock, 2009). 
Subsequent studies have found that hypertensive medication could be protective 
against vascular dementia and other types of dementia, other than DAT (Chang-
Quan et al., 2011), although they lack the methodological robustness of a 
Cochrane review. However, the relationship between hypertension and cognitive 
decline is still not well understood (Liou et al., 2015). This is possibly explained 
by the variation used in instruments of measurement e.g. parameters of 
hypertension diagnosis or cognitive assessment tools chosen.  
 
1.13.3 Cognition and cardiovascular risk factors 
Cardiovascular risk factors refer to smoking, hypertension, and diabetes, that 
seem to mediate the development of cardiovascular conditions e.g. CVD, stroke, 
ischemic heart attack and so on. Over a period of eight years in a community 
sample, Anstey, Sargent-Cox, Garde, Cherbuin and Butterworth (2014) found 
that considered collectively, these risk factors were associated with cognitive 
decline, and specifically with processing speed, which has already been 
implicated as a domain that may be affected in diabetes.  
 
A recent meta-analysis has used the data from 19 different studies, involving 
54,000 participants, and used cardiovascular risk factors to compute an overall 
composite cardiovascular risk score. This score was highly correlated with lower 
cognitive test performance and was deemed to be a useful as a predictive 
measure of cognitive functioning (DeRight, Jorgensen, & Cabral, 2015).  
 
1.13.4 Cognition and High Cholesterol 
High cholesterol in middle age has been found to have a deleterious affect on 
cognitive function in later life (Whitmer, Sidney, Selby, Johnston, & Yaffe, 2005). 
However, as people get older, the relationship between high levels of cholesterol 
and cognition is not clear. The majority of research indicates there is no 
association between cognitive impairment and cholesterol in older people 
(Kerola, Kettunen, & Nieminen, 2011). Some research has hypothesised that this 
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lack of relationship between cognition and lipids in older people may be because 
of existing vascular pathologies in this population (Ancelin et al., 2014). More 
recently, this lipid-cognition relationship has been explored in Chinese 
populations, and it was concluded that high cholesterol was associated with 
faster global cognitive decline in older people (Ma et al., 2017).  
 
1.13.5 Cognition and obesity 
Early research had indicated that the relationship between obesity and cognitive 
decline, particularly dementia, was unclear. There is some evidence to suggest 
that as with hypertension, a u-shaped association has been found between BMI 
status and dementia, specifically being underweight or overweight – that both are 
risk factors for developing dementia (Beydoun, Beydoun, & Wang, 2008).  
Furthermore, when controlling for other dimensions of metabolic syndrome e.g. 
impaired fasting glucose, hypertension and dyslipidemia, obesity seems to be an 
independent risk factor for the development of DAT. Indeed, over a 10-year 
period examining the connection between metabolic status and BMI, individuals 
with obesity who were otherwise metabolically healthy showed a similar rate of 
cognitive decline to their metabolically disturbed counterparts, with an 
acceleration of cognitive decline associated with increasing BMI (Singh-Manoux 
et al., 2012). The association between obesity and cognition is also seen in later 
older age, with waist circumference being positively correlated with poorer 
cognition in elderly women (West et al., 2016). 
 
In summary, hypertension, dyslipidaemia, obesity and cardiovascular factors all 
seem to impact on cognitive function, with or without diabetes. On the one hand, 
these aspects of health seem to mediate the relationship between cognitive 
functioning and diabetes, but on the other act as independent risk factors for 
cognitive decline, in their own right. With these existing hypotheses in place, the 
next consideration is how diabetes can impact the brain at the structural level.  
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1.14 Diabetes and CNS Neuropathology 
 
1.14.1 Structural Changes 
There are certain areas of the brain and structural changes that are typically 
affected in diabetes. For example, research has found a relationship between 
diabetes and a reduction in grey matter density, changes in white matter, atrophy, 
and brain volume loss (Seaquist, 2010; Erus et al., 2015). However, these are 
general changes that are usually secondary to primary problems, and so making 
a direct causal link between diabetes and these structural changes is difficult 
because of the confounding aspects of the comorbid conditions of diabetes. 
Manschot et al. (2006) found that people with T2DM showed cognitive 
impairment and structural changes, including increased brain atrophy – e.g. brain 
wasting, compared to people that did not have diabetes. They hypothesise that 
these cognitive deficits were related to these structural changes in the brain, most 
likely due to vascular problems and/or cognitive aging. Later research has also 
implicated brain atrophy as a mediating factor in developing cognitive impairment 
in T2DM, rather than cerebrovascular lesions (Moran et al., 2013). Therefore, it is 
still unclear as to how brain structure interacts with cognition and diabetes. 
 
1.14.2 Glucose 
There is still some uncertainty as to where in the brain may be affected by high 
levels of glucose, and therefore the skills or intelligence that it may impact. 
The brain uses about 20% of all sugar energy in the body, despite only 
accounting for around 2% of body weight (Erbsloh, Bernsmeier, & Hillesheim, 
1958): this equates to approximately 5.6mg glucose per 100g brain tissue per 
minute. As the brain depends on glucose as its main source of energy, the 
importance of glucose regulation cannot be downplayed: neurons are generally 
intolerant of any disruption to the energy supply to the brain and diseases can 
develop as a result (Mergenthaler, Lindauer, Dienel, & Meisel, 2013). However, 
factors other than physiology may also affect an individual’s cognitive function.  
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1.15 Effects of cognitive decline in managing Diabetes 
 
To effectively manage diabetes, one is required to employ a rigorous self-
management program (Peel, Douglas, & Lawton, 2007). A daily regime may 
include medication, injections, carbohydrate counting, daily blood glucose 
monitoring, and exercise, although this list is not exhaustive.  In order to 
comprehend why one would need to employ such a regime, requires a basic 
understanding of the condition. Furthermore, to cope with the multiple 
components of managing diabetes requires patients to be cognitively intact to a 
sufficient level.  In people that have had the condition a long time, this is even 
more important because of the complication risks associated with increased 
duration of illness (Hewitt, Smeeth, Chaturvedi, Bulpitt, & Fletcher, 2011).  
 
1.15.1 Research into the impact of cognitive decline on managing diabetes 
The issue of the impact of cognitive impairment on diabetes self-management 
was highlighted over 15 years ago. Sinclair, Girling, & Bayer (2000) found that in 
older adults with T2DM who were cognitively impaired, patients employed worse 
self-management behaviours, needed more professional support and were more 
likely to have been admitted to hospital in the last 12 months, than those with 
intact cognition. There is thought to be some variation in the impact of cognitive 
impairment on daily living for people with diabetes and most of the evidence 
currently focuses on older adults. In younger adults, cognitive impairment could 
be linked to severe episodes of hyperglycaemia, but much of the evidence for 
which domains are affected is variable  (Kodl & Seaquist, 2008). Therefore, it is 
difficult to ascertain what cognitive skill is most compromised by poorly controlled 
diabetes.  
 
1.15.2 Cognitive domains that matter in diabetes management 
Munshi (2017) has highlighted the different cognitive domains that if impaired, 
could interfere with effective diabetes self-management. For example, any 
change in memory could mean one forgets to: take medication or inject, monitor 
your blood glucose, eat food regularly, or attend a diabetes appointment. Any 
problem in executive function could lead to problems with remembering 
instructions and/or putting them into practice, trying new suggestions, or the 
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increased risk of making mistakes when implementing these changes. There 
could be a similar issue with any problems in processing speed, as this requires 
ability to attend to information flexibly and within a given time frame, for example, 
at a clinic appointment. Finally, problems with attention could entail that a patient 
cannot focus wholly on the instructions they have been given. Whilst Munshi 
(2017) does not emphasise which of these domains is most important, there is an 
indication that each domain has implications in managing diabetes effectively. Of 
concern is that the relationship between cognitive dysfunction and well-controlled 
diabetes in older adults is bi-directional (Munshi et al. 2006): the more cognitively 
impaired one is, the worse your glycemic control tends to be, developing into a 
potential vicious cycle (Ojo & Brooke, 2015). This is one of several factors that 
may not be currently accounted for in typical diabetes management regimes.   
 
1.16 Intersection of Diabetes, Cognition and Context 
 
Within the epidemiology of diabetes, there has been a focus on individual risk 
factors and ascribing them to a resulting biological outcome, in a causal link. 
However, this can overlook some of the more social factors that can lead to the 
‘fundamental causes’ of disease (Link & Phelan, 1995). The term fundamental in 
this context refers to factors that cannot be eliminated by a healthcare 
intervention, such as low income or geographical location.  
 
1.16.1 Diabetes and Poverty 
A major mediator in pathogenesis of diabetes is poverty. According to research 
looking at the influence of socioeconomic status of people with T1DM and T2DM, 
in deprived areas there are more people who have T2DM but not T1DM (Evans, 
Newton, Ruta, MacDonald, & Morris, 2000). There was also a connection with 
obesity, where an increase in deprivation was linked to a higher BMI. The impact 
of SES on healthcare outcomes seems multifaceted, as highlighted by Lutfey and 
Freese (2005) who looked at the health outcome of two clinics for diabetes care, 
which differed drastically in socioeconomic terms. They found that the differences 
in SES status, led to variations in the way the clinics were run on a multitude of 
levels, leading to poorer health outcomes for those in the lower SES clinic. The 
higher-SES population understood their condition better and the staff provided 
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better care continuity with these patients. Yet, disproportionately more resources 
were given to the higher SES clinic than the lower SES clinic, entailing worse 
diabetes management for the latter group.  
 
More recently, the Commission on Social Determinants of Health (2008) has 
highlighted that many health outcomes are socially determined. In order to tackle 
these issues, they suggest the intervention should be focused not just on the 
biological risk factors of developing conditions but also at addressing these 
inequities. In a population study of Latinos in the United States with T2DM, 
Chaufan, Davis, & Constantino (2011) found that whilst participants were fully 
aware of what they needed to do to manage their diabetes (e.g. eating healthily, 
exercise and other diabetes-related treatment), they were prevented by doing so 
because of their ‘poverty trap’ and their circumstances were often precarious. 
Despite their personal efforts in attempting to ‘treat’ their diabetes, they were 
unlikely to succeed in their endeavours because of the structural inequities at 
play in their lives.  
 
1.16.2 Cognition and Poverty 
Research has also focused on the ways that being in a low SES group can 
further perpetuate poverty. One hypothesis proposed by Mani, Mullainathan, 
Shafir, & Zhao (2013) was that poverty requires a different process of thinking 
that is distinguishable from people who are affluent. Therefore, the mental 
resources required to think about financial management leave little capacity to 
think about anything else. In both laboratory and field tests, the authors 
supported this claim and emphasised that being poor means having less 
cognitive capacity, in addition to having a lack of funds. They argue that their 
conclusion is not about poor people per se but about the people who find 
themselves in poverty.  
 
Some attempts have also been made to explore the sequelae affected by 
poverty. The extent to which poverty and aging affects cognition functioning was 
examined in a large population sample to see if socioeconomic status in later life 
was associated with cognition. Zhang et al. (2015) found that after controlling for 
demographic factors such as age, education and gender, poverty was 
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independently associated with lower processing speed. The authors concluded 
that improving SES would also improve some domains of cognitive functioning in 
older adults. Looking across the life span, in a cross sectional study, Latin 
American children who did not have their basic needs met and those who did, 
were compared on performance in cognitive tests. It was indicated that those 
children who were in poverty showed a significantly lower performance in 
executive function, namely working memory and word fluency, and also attention 
(Lipina et al., 2013). These environmental factors are important to consider, 
especially with the increased prevalence of physical health problems as a result 
of social and structural inequalities.  
 
1.17 Young people with T2DM 
 
Until recently, T1DM was considered the form of diabetes that children and young 
people were most likely to develop and diagnoses of other phenotypes was quite 
a rare phenomenon (Constantino et al., 2013). However, an epidemiological 
study in the last two years found the incidence of T2DM had been 
underestimated and was now the most common type of diabetes in in young 
people aged 5-29 in some parts of the world (Ke, Sohal, Qian, Quan, & Khan, 
2015).  
 
As in adults, diagnoses of T2DM in young people are typically lifestyle-related. 
However, there are a number of questions about the pathophysiology in this 
population, as T2DM in young people is less understood (Adamo & Caprio, 
2011). Attempts at estimating the impact of developing T2DM at a younger age 
have put the average life expectancy of someone as 15 years less compared to 
someone without diabetes (Rhodes et al., 2012). Furthermore, with the onset of 
T2DM in adolescence or young adulthood, the severe complications that can 
develop with the condition e.g. cardiovascular problems, were predicted to occur 
in a person’s 40s. When comparing mortality rates of people with T1DM and 
T2DM, the mortality was increased nearly two-fold, which was often premature 
death due to cardiovascular disease. This makes younger onset T2DM the more 
dangerous of the phenotypes to develop (Constantino et al., 2013). As a result of 
these mortality rates in young onset T2DM, Public Health England have called for 
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a nationwide diabetes prevention program as they estimated that over 10% of 
people under 16 were at risk of developing T2DM (Public Health England, 2015).  
 
One area where there seems to be more evidence regarding is in retinopathy in 
young onset T2DM. Research in the UK has found that developing T2DM in 
younger age, e.g. onset under 40, leads to aggressive retinopathy in around 80% 
of participants after 15 years, irrespective of the age of diagnosis (Song, 2016). 
Of concern was that this debilitating condition would affect people during their 
working years and that younger people may be at higher risk of developing other 
diabetes-related conditions (Pulgaron & Delamater, 2014). In the wider research 
community, there is an acknowledgement that it will take some time to better 
understand the pathogenesis and impact on services of younger onset T2DM 
(Constantino et al., 2013; Wilmot & Idris, 2014). 
 
1.18 Rationale 
 
Understanding diabetes and how it develops is of great importance in the world 
today, because of the multifaceted impact the condition has on health, economy 
and society at large. When the onset of T2DM is at a younger age, the comorbid 
conditions one can develop are thought to have a greater impact, such as 
aggressive retinopathy. Young people will experience the debilitating effects of 
these conditions during a period in which they are expected to be most active.  
 
Cognitive impairment is a significant complication of diabetes and there is an 
established evidence base that it occurs in older adults with diabetes. It was 
initially hypothesised that this was partially related to how long a person had the 
condition. However, there is some emerging evidence to suggest that cognitive 
changes can be observed in the early stages of the condition (Ruis et al., 2009). 
In 2015, T2DM became the most common phenotype of diabetes in children in 
some parts of the world (Ke et al., 2015) and as yet, the aetiology of it in this 
population is unknown.  As cognitive impairment can have significant implications 
for diabetes management (Munshi, 2017), it will be important to investigate if this 
reduced cognitive functioning is observed in younger populations with T2DM.  
Diabetes already entails a large treatment burden, and mild cognitive impairment 
  24 
is likely to complicate people’s ability to manage their diabetes, as it does in older 
adults (Sinclair et al., 2000).  
 
If this relationship is found in younger adults, then cognitively impaired individuals 
may struggle with the diabetes treatment regime as currently recommended 
(National Institute for Health and Care Excellence, 2016b).  To address this issue 
in older adults, there are adapted forms of treatment suggested for those affected 
cognitively (Kirkman et al., 2012) and younger adults could need their care 
package adapted accordingly. In the instance that no cognitive impairment is 
observed in working age adults with T2DM, then this could indicate a crucial 
period in which interventions could ‘preserve’ cognitive functioning. There have 
also been suggestions for more routine screening for cognitive impairment in 
older adults as part of diabetes management (Sinclair et al., 2000; Cukierman, 
Gerstein, & Williamson, 2005), and this research could contribute toward similar 
conclusions for younger populations. 
 
Furthermore, there is little in the current literature that discusses or assesses the 
premorbid functioning of people with diabetes in the context of their cognitive 
impairment (Xia et al., 2013; Monette, Baird, & Jackson, 2014). Therefore, it 
would be useful to address this gap by using a measure to test this domain in 
people with T2DM, to assess its utility.  
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1.19 Aims and Research Questions: 
 
There is an identified link between T2DM and cognitive impairment in later life 
and from middle age. However, it is unclear if this link will be observed in younger 
adults with T2DM, as current literature does not focus on this age range. 
Therefore, this study aims to investigate the cognitive function of working age 
adults with T2DM aged 18-55. Using cognitive assessments, the questions I will 
pose are: 
 
• Do working-age adults with T2DM show reduced cognitive function in 
scores from a battery of neuropsychological measures, compared to the 
established norms of cognitive tests?    
 
• As existing literature in the field has tended to neglect the formal 
assessment of premorbid functioning, do working-age adults with T2DM 
exhibit reduce cognitive function to their own optimal/premorbid ability 
level? 
 
• If cognitive impairment is observed, to what extent is this related to health 
indicators related to diabetes, specifically Hba1c and lipid profile? 
 
• How do other demographic factors e.g. age, duration of condition, interact 
with T2DM and cognitive function in working age adults? 
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2.  METHODOLOGY 
 
 
2.1 Epistemology 
 
Epistemology is defined as the study of how we have acquired knowledge and 
view the world as we do. All types of research attempt to investigate and evaluate 
aspects of the world. Therefore, in order to conduct research, one has to adopt 
an epistemological position. Hamlyn (1970) outlines four epistemological 
positions: correspondence theory – which states a belief is true if it matches 
reality; coherence theory – a belief is true if it is logical and internally consistent; 
consensus criterion – something is true if a group of people hold it; and the 
pragmatist criterion – a belief should be upheld if it is useful. I will outline 
positions akin to these in more detail: 
 
2.1.1 Positivism 
Scientific and quantitative research has tended to adopt a positivist approach that 
purports the world has properties, which are observable and measurable, via 
sensory phenomenon. This empirical approach – that knowledge is derived from 
the abstraction of mental states – has led to the assumption that science is 
objective and free from values (Barker, Pistrang, & Elliott, 2002). This approach 
has been widely critiqued in social sciences, for obscuring contextual factors, 
which lead us to generate certain conclusions and privilege types of knowledge 
over others.  
 
2.1.2 Critical Realism 
The critical realist point of view evolved from a correspondence theory 
perspective and was developed to answer the question of whether society could 
be studied as nature is (Bhaskhar, 1998). This view assumes the world exists 
independently of what we think about it, and secondly, our knowledge could be 
fallible about it, and so we cannot be certain about our conclusions.  Whilst 
elements of this approach are appealing, this approach values knowledge to a 
greater degree than is necessary and in my view, does not privilege the 
contingencies of where we have come from enough. 
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2.1.3 Pragmatism 
There is no singular definition of pragmatism (Lipscomb, 2011). However, the 
type of pragmatism I adopt, views ideas such as ‘truth’ and ‘reality’ as normative; 
therefore, we can never be sure that what we observe and the conclusions we 
make are not influenced by our values or accurately reflect the world around us 
(Zaccharadis, Scott, & Barrett, 2010). It also allows research to be conducted 
using a rigorous methodology, with the ‘what works’ philosophy (Howe, 1998). 
This commitment to certain views and practices (rather than knowledge) 
compliments my own perspective of neuropsychology, and allows me to measure 
aspects of these beliefs in order to progress.  
 
2.1.4 Neuropsychology 
Like positivism, neuropsychology also privileges certain knowledge, specifically 
examining the relationship between behaviour and brain function. Originating out 
of single case studies used in medicine, its birth is located back to 1861, when 
Broca identified an area of the brain associated with a speech difficulty in an 
individual (Luria, 1973). Whilst these idiographic methods are less favoured 
nowadays, nomothetic approaches that look at groups of individuals are 
preferred. However, within a framework of falsification, idiographic or individual 
cases are still used as counter examples to existing theory in a certain domain. In 
these instances, having a contextual understanding of these counter examples to 
existing theory can be essential to understanding ‘what works’. 
 
2.1.5 My position 
In summary, pragmatists conduct research in relation to their personal value 
system (Teddlie, 2005). I believe finding out if people with diabetes are being 
overloaded by their treatment, is of value. Through my clinical work, I have seen 
how difficult diabetes can be to manage, and how people get treated when they 
cannot manage their diabetes. I had always wondered whether there was 
something that was being missed from their care; perhaps understanding 
people’s psychological wellbeing and cognitive state within a different framework 
would help management of the physical demands of the condition? As such, my 
connection to research is a pragmatist perspective – one’s cognitive state exists 
without us examining it. We may be mistaken in our approach, and we should 
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use ‘what works’ to investigate it, being mindful this is both a local and Western 
position and may not be equivalent across all cultures (Van de vijver & Poortinga, 
1997; Fernandez & Marcopulos, 2008) 
 
2.2 Design 
 
The study employs a cross-sectional correlation design, which looks at the 
relationship between cognitive impairment (dependent variable) in a population 
who has T2DM, and relates it with a number of independent variables: diabetes 
status (comparing the sample to existing norms), premorbid functioning, diabetes 
control (Hba1c – continuous) and diabetes-related factors (age, duration of 
diabetes, education level and lipid profile). In the diabetes context, ‘cognitive 
function’ alleges four main domains: processing speed, memory, attention and 
executive function. This design also allows one particular group to be compared 
to other participants for tests of reliability and difference.  
 
2.2.1 Control group 
Initially, there was a plan to include a control group with live-in or home controls 
e.g. spouse or house mate to do cognitive testing, which would enable 
comparison to the test population. This would offer a more robust way to examine 
cognitive performance of people with diabetes in contrast to people without. 
However, due to a delay in getting ethical approval, this was not practically 
possible. As such, the decision was made to use the established age-specific 
norms reported for each test as a comparison. In addition, the population-
distributed scores were compared to the putative norms from the subtests in the 
battery. This approach was taken due to the time and resources available.  
 
2.3 Recruitment 
 
Participants were recruited from one NHS setting that offers integrated diabetes 
care in the community: the Camden Integrated Practice Unit. A consortium of 
NHS trusts in the North of London commissions these services. They provide a 
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multi disciplinary team approach to Diabetes management including nurse 
specialists, diabetes and endocrinology consultants, podiatrists, dieteticians, and 
psychologists.  
 
2.3.1 Eligibility Criteria 
People with a diagnosis of T2DM can also have several other physical health 
issues, psychological difficulties and comorbidities. These factors can impact on 
several areas of functioning, including cognitive capacity. As such, eligibility for 
the study was informed by existing knowledge from the literature review 
regarding older adults, T2DM and cognitive impairment. 
 
Whilst inclusion and exclusion criteria were established from the outset, a 
potential participant’s recruitment to the study was decided on an individual basis 
and was partially informed by the referring clinicians’ knowledge of the patients 
characteristics.  
 
Therefore, the criteria for selection for the study were: 
 
2.3.1.1 T2DM diagnosis: participants were required to have a diagnosis of T2DM. 
Patients at the unit could have either T1DM or T2DM. In addition, it is not always 
possible to distinguish between the two phenotypes of diabetes. If there was any 
ambiguity about this in patients at the recruitment stage, they were not contacted. 
 
2.3.1.2 Demographic information: participants had to be adults aged 18-55, with 
an understanding of written and spoken English. If patients were able to talk to 
their referring clinician and follow their written care plan without an interpreter – 
professional or family member - then they could be tested using the battery of 
measures.  
 
2.3.1.3 Absence of diabetic complications: significant comorbidities would be 
prohibitive for participants taking part in the research. For example, one patient 
had diabetic retinopathy, which is damage to the eye caused by high blood 
sugars. However, he was being treated and his vision was relatively unaffected. 
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2.3.1.4 Medical comorbidities: People with diabetes present with a range of 
difficulties that can arise before or after developing the condition, some of which 
can affect cognitive functioning. For example, hypertension (high blood pressure) 
and cardiovascular disease are linked to cognitive impairment (Kilander, Nyman, 
Boberg, Hansson, & Lithell, 1998; Hassing et al., 2004; Gorelick et al., 2011). 
There has also been some controversial evidence to suggest that dyslipidemia 
(high levels of blood fat) is linked to Alzheimer’s and other dementias (Reitz, 
2013; Moon, 2016), but this was not used to rule people out from recruitment. 
However, their lipid profile was recorded.   
 
Should participants have comorbidity, their inclusion was considered on an 
individual basis. For example, if the patient had hypertension, the clinician’s view 
on whether it was well controlled e.g. managing their hypertension within the 
limits of recommended medical guidance (National Institute for Health and Care 
Excellence, 2016a) was taken into account before people were recruited. 
 
2.3.1.5 Other conditions associated with cognitive impairment: participants with 
muscular sclerosis (MS) were not eligible to participate in the study due to the 
widespread effects it can have on cognition. The areas of functioning that MS 
tends to effect are information processing, attention, long-term memory and 
executive function (Chiaravalloti & DeLuca, 2008) – the same areas we 
anticipated would be impacted in T2DM.  
 
Secondly, we also liaised with clinicians if prospective participants had 
experienced a stroke, as there is an increased risk of cognitive impairment 
following one (Gorelick et al., 2011).  
 
2.3.1.6 Mental Wellbeing: In neuropsychological assessment, there is little 
subcortical specificity for tests administered. Therefore, it is useful to measure 
emotional wellbeing, to assess whether obtained scores for participants could be 
explained by an alternative explanation (Hebben & Milberg, 2009). 1 in 5 people 
with T2DM diabetes also have depression (Ali et al., 2006) and any diagnosis of 
diabetes is associated with the development of other affective disorders, such as 
anxiety (Kruse et al., 2003). Developing mental health problems has been linked 
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to the treatment burden, both psychological and physical, of having diabetes, as 
the treatment regime relies heavily on strict self-management. On the back of this 
knowledge, routine questionnaires were given in the clinic to newly referred 
patients so information about the emotional wellbeing of patients was available. 
Therefore, any patient who was waiting for psychological assessment from the 
diabetes psychologist or was currently in treatment was discussed before being 
offered the chance to participate in research.  
 
People with ‘severe mental illness’, who had received a diagnosis of bi-polar 
disorder or schizophrenia were also considered but assessed for possible 
confounding factors e.g. neuroleptic medication.  
 
 
2.3.2 Recruitment Process 
Using the above criteria, eligible participants were identified by the clinician of the 
service, by checking the patient information system database of patients who 
were attending clinic that week. Initially, potential participants were approached in 
the waiting room. However, this was not successful for two reasons: one, I had 
no advice from their clinician if they were suitable and two, patients experienced 
this as stressful. 
  
Therefore, we agreed a record would be kept of which patients were eligible to 
participate from a clinician’s diary, and clinicians would be contacted two days 
before their appointment to ask 1) would they be suitable and 2) if so, would that 
patient mind being called about participating in research. If patients said yes to 
being contacted, participants were offered an information sheet (see Appendix A) 
at their appointment. This approach was much more successful and all 
participants were recruited in this manner.  
 
Potential participants were contacted and the study was discussed with them 
over the phone. Of the people contacted, only two people declined to take part. 
Those who agreed to participate were offered a date and time to attend the 
hospital.  
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2.4 Sample Size 
 
A power calculation was computed for the study in question. If the effect size was 
0.8 in a study with two types of predictor e.g. T2DM and cognitive impairment, 
and, a sample size of 10, a power calculation using G-power indicates a level of 
0.32, which is particularly small, indicating just over a 30% chance of detecting an 
effect if one exists. Whilst this sample size is tied to time and resources, previous 
studies in this area have adopted similar sized samples. For example, Zhil, 
Schaaf and Zillmer (2010) who investigated the relationship between 
neuropsychological profiles of T1DM and T2DM and hypoglycaemic control used 
a sample size of 12 for their treatment arm for T2DM. Baker et al., 2011 also 
used similar sample sizes, comparing a group of older adults with high blood 
sugar (N=11) to those with a diagnosis of diabetes (N=12). In addition, a high 
statistical power does not necessarily imply credibility of results (Sullivan and 
Feinn, 2012). However, it is emphasised that the study was exploratory in nature 
and so results will be interpreted with caution. 
 
2.5 Ethical Issues 
 
2.5.1 Ethical Approval 
Ethical approval was obtained from NHS Northumberland Ethics Committee, with 
provisional approval initially (see Appendix B). Once I had made the agreed 
changes with an accompanying letter (see Appendix C), I received a favourable 
opinion (see Appendix D).  Following HRA approval (see Appendix E), the 
Research and Development Department for the Hospital awarded the study 
access to its patients (see Appendix F).  
 
Ethical approval was also sought from the University of East London ethics 
committee (see Appendix F). With both of these favourable opinions from the 
NHS and UEL, I was provided UREC Sponsorship from the university (see 
Appendix G).  
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2.5.2 Confidentiality & Anonymity 
Record sheets were numbered to maintain anonymity, and the researcher kept a 
copy of the names of participants separately, which was password-protected, on 
an encrypted server. Following testing, all tests were scanned and stored 
digitally, individually password-protected and hard copies were destroyed.  
 
All aspects of testing remained confidential unless there were concerns about a 
participant’s safety or that of others. In the instance where concerns arose, 
supervisors were contacted, as were other relevant professionals. All of these 
steps were discussed with the participant before proceeding. 
 
The researcher had access to participants’ medical history via their referring 
clinician and the relevant electronic record (e.g. EMIS), with supervision.  
 
2.5.3 Informed Consent 
Participants were given an information sheet (if not already received) to read 
before signing a consent form (Appendix G). Participants were given an 
opportunity to ask questions and were encouraged to do so throughout. Testing 
only began when consent forms were signed. Participants were given the right to 
withdraw at any time. 
 
2.5.4 Harm Minimisation 
A comfort break was offered part way through the session and participants were 
made aware of this at the beginning of testing. This is to minimise the fatigue that 
can be experienced when completing neuropsychological tests. Participants were 
monitored and asked how they were experiencing the tests over the duration of 
their assessment. At the test completion, participants were asked if they had any 
concerns about taking part or their performance. 
 
2.6 Procedure 
 
Testing took place in a meeting room or in a clinical room in the hospital. The 
assessment was completed in one session and took between 60 and 90 minutes 
to complete.  
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Initially, demographic information was obtained from participants, including DOB 
and ethnicity. Next, a short medical history was taken, which included questions 
about head injury, stroke, MS and kidney problems. 
 
Following this, the battery of neuropsychological tests was administered. The 
interview protocol was adhered to for each participant (see Appendix J). Once 
testing was completed, participants were debriefed verbally and given a written 
debrief sheet including sources of support e.g. Diabetes UK (Appendix K).  
 
Following analysis of their assessment, each participant was sent a written 
summary of their relative strengths and weaknesses, recommendations for their 
future care, and an appendices of their scores (should they wish to be or were 
recommended to be re-tested in the future). As agreed with participants, a copy 
was sent to their Diabetes clinician. This summary also gave contact details for 
the researcher and for their relevant professional at the service, should they want 
to discuss their results.  
 
Relevant medical values regarding their diabetes were also recorded, although 
this was done via the patient information system with the patient’s permission: 
duration of diabetes, diabetes control e.g. Hba1c and Lipid Profile. A blank copy 
of the record form is available in the appendices (see Appendix L). 
 
2.7 Materials 
 
The tests chosen were selected for their appropriateness for assessing the 
constructs that are affected by diabetes: attention, processing speed, memory 
and executive function. As previously described, much of the literature into 
cognitive impairment is with older adults. Therefore, tests were selected in 
concordance with other studies, which assessed processing speed (Stewart & 
Liolitsa, 1999; Awad et al., 2004), verbal and visual attention (Manschot et al., 
2006), executive function (Rucker, McDowd, & Kluding, 2011; Vincent & Hall, 
2015) and memory (Arvanitakis et al., 2006; Van Harten et al., 2007; Redondo et 
al., 2015). 
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2.7.1 Optimal Ability 
It is important to estimate the optimal ability or premorbid functioning in 
neuropsychology as a baseline by which to measure any form of cognitive 
impairment (Hebben & Milberg, 2009). In order to do this, the Test of Premorbid 
Functioning (TOPF) (Wechsler, 2011) was used. This assesses reading ability by 
presenting the subject with 70 irregularly spelled words, which they are asked to 
pronounce. The irregular grapheme-to-phoneme require previous knowledge of 
the word in order to read them, for example, the silent ‘b’ in plumb. In addition, 
the TOPF has been validated and co-normed with the Wechsler Adult Intelligence 
Scale-IV (Wechsler, 2008) and Wechsler Memory Scale-III (Wechsler, 2009). As 
highlighted in the earlier literature review, this study deemed assessment of 
optimal ability as equally important as other domains of cognitive functioning, 
especially as so few studies in the existing literature assessed optimal ability 
(Cosway et al., 2001). 
 
2.7.2 Verbal Attention 
Subtests from the WAIS-IV (Wechsler, 2008) were used to assess verbal 
attention. 
 
2.7.2.1 WAIS-IV digit span forward: Digit span forward is a measure of verbal 
short-term stores (STS). It presents numbers orally, in a string of two to nine and 
asks participants to repeat them immediately back to the examiner.  
 
2.7.2.2 WAIS-IV digit span backward: measures STS plus the ability to 
manipulate information. A string of two to nine numbers is presented and 
participants are asked to repeat them back to the examiner in reverse order. 
 
2.7.2.3 WAIS-IV digit span sequencing: measures STS and the ability to control 
that information. This also requires participants to repeat back orally presented 
numbers in sequence, from lowest to highest, from a string of two to nine digits in 
length.  
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2.7.3 Processing Speed 
Subtests from the WAIS-IV (Wechsler, 2008) and Delis-Kaplan Executive 
Function System (DKEFS) (Delis, Kaplan, & Kramer, 2001) were used to assess 
processing speed (the ability to do tasks quickly without error).  
 
2.7.3.1 WAIS-IV digit symbol coding: measures the speed in which examinees 
substitute symbols with a matched key of digits, numbered one to nine, over a 
two minute period.    
 
2.7.3.2 DKEFS colour word inference – colour word naming: tests how quickly 
blocks of colour can be named, displayed in red, blue or green. This provides a 
baseline of a participant’s speed of verbal output. 
 
2.7.3.3 DKEFS colour word inference – colour word reading: adapted from the 
stroop framework, this task assesses how quickly the words red, blue or green, 
can be read. This gauges speed of verbal output in the participant. 
 
2.7.3.4 DKEFS trail making test – visual scanning: this paper-and-pencil task 
tests how quickly the number ‘3’ can be identified amongst other digits, numbered 
one to nine, and cancelled out with a pencil stroke. It provides an estimation of 
visual-motor scanning speed for the examinee.   
 
2.7.3.5 DKEFS trail making test – number sequencing: measures how quickly 
numbers one to nine can be identified and connected in sequential order on a 
page of numbers and letters, ‘a’ to ‘p’. It provides an estimation of visual-motor 
scanning speed for the examinee.   
 
2.7.3.6 DKEFS trail making test – letter sequencing: tests how quickly letters ‘a’ 
to ‘p’ can be identified and connected in alphabetical order on a page of letters 
and numbers, one to nine. It provides an estimation of visual-motor scanning 
speed for the examinee.   
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2.7.4 Learning and Memory 
The Wechsler Memory Scale III (Wechsler, 2009), tests both visual and verbal 
learning and memory. 
 
2.7.4.1 WMS logical memory: assesses the ability to retain 25 pieces of 
information based on two stories given, immediately after being presented and 
with a 20-minute delay. Following delayed recall, participants are asked yes or no 
questions, which include cues regarding both stories.  
 
2.7.4.2 WMS visual reproduction: measures how well seven designs of 
increasing complexity that are presented for ten seconds, can be reproduced on 
paper immediately and with a 20-minute delay. Following delayed recall, 
participants are presented with six options for each of the seven designs and 
asked to correctly name the design that was shown. 
 
2.7.5 Executive Function 
Three subtests from the Delis-Kaplan Executive Function System (DKEFS) (Delis 
et al., 2001) were used to assess this domain:  
 
2.7.5.1 DKEFS verbal fluency: timing participants for 60 seconds to assess a) 
letter fluency –naming as many words beginning with the letter ‘F’, ‘A’ or ‘S’; b) 
category fluency – naming as many words that fit the category ‘Animals’ or ‘Boys 
Names’; c) switching fluency – naming a word from one category, fruit, and then 
switching and naming a word from a different category, furniture, and alternating 
for the task duration. It assesses the speed of lexical and semantic speech and 
output. 
 
2.7.5.2  DKEFS colour word Inference – inhibition and switching: inhibition 
measures cognitive flexibility by requiring participants to name the colour ink as 
quickly as possible, whilst the written word is displayed in a discordant colour. 
The switching task measures the ability to swap between naming the colour ink 
and naming the ink the word is written in, whilst the word is displayed in a 
discordant colour. It assesses the capacity to inhibition an irrelevant task.  
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2.7.5.3 DKEFS trail making test – number letter switching: assesses how quickly 
letter and numbers can be connected by pencil in sequential and alphabetical 
order on a page of both numbers and letters e.g. 1-A-2-B. It assesses the 
capacity to switch between mental sets.  
 
2.7.6 Verbal and Visuo-spatial Functions: 
 
2.7.6.1 WAIS similarities: tests verbal abstraction and requires examinees to 
describe how two orally presented words are similar (e.g. ‘yellow’ and ‘green’, are 
both colours). The task has 18 word pairs and the task increases with difficulty.  
 
2.7.6.2 WAIS block design: assesses perception and construction by requiring 
participants to assemble blocks of two, four or nine into a target design. These 
designs increase in difficulty and are time limited, with more points being 
awarded the quicker the task is completed.  
 
2.7.7 Mood 
 
2.7.7.1 Beck anxiety inventory (BAI) (Beck & Steer, 1993): is a 21-item self-report 
measure that includes common symptoms of anxiety. Responders state how 
much they have been bothered by symptoms in the last week on a four-point 
scale: not at all, mildly, moderately, and extremely.   
 
2.7.7.2 Beck depression inventory (BDI) (Beck, Steer, & Brown, 1996): is a self-
report measure compiled of 21 items of common symptoms of depression. The 
severity that the responder has experienced each symptom over the last two 
weeks is indicated by choosing the statement that most applies to them.  
 
2.8 Analysis 
 
The ‘raw’ scores obtained were converted into scaled scores (Mean =10, SD=3). 
A copy of the conversion table from scaled scores to labels is available in 
Appendix M. These scores were inputted into the Statistical Package for Social 
Sciences (SPSS), version 23. Analyses were performed in accordance with the 
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parameters of the data e.g. small sample size, which is explained further in the 
results section. 
 
If the effect size was 0.15 in a study with two types of predictor e.g. T2DM and 
gender, and the number of predictors was four e.g. age, years of education, 
duration of condition, a sample size of 11, a power calculation using G-Power 
indicates a level of 0.60. Whilst this sample size is tied to time and resources, 
previous studies in this area have adopted similar sized samples (Zhil et al., 
2010; Baker et al., 2011). 
 
2.9 Participant Characteristics 
 
In total, 10 participants with T2DM were recruited and completed testing. The 
characteristics of participants are detailed in Table 1. The participants aged 
between 34 and 55, with a mean age of 44.9 (Standard Deviation [SD]: 9.19). 
   
Table 1  
Descriptive Statistics for Participant Characteristics.  
 Mean SD Min Max Skewness Kurtosis Shapiro-Wik Sig 
Age (Years) 44.90 9.20 30 55 -.747 -1.094 .089 
Education (Years) 13.8 2.57 10 17 -.080 -1.326 .896 
Duration 72.90 66.90 8 180 .596 -1.332 .065 
Hba1c 76.15 21.30 38.8 106.0 -.151 -.723 .725 
Total Cholesterol 4.05 1.01 2.2 5.6 -.005 .418 .599 
HDL 1.08 .33 .7 1.7 .824 -.004 .171 
LDL 2.00 .88 .6 3.6 .342 .368 .910 
Triglycerides 2.15 1.21 .7 4.8 1.161 1.341 .189 
Beck Depression 16.10 12.22 0 36 .109 -1.296 .495 
Beck Anxiety 15.00 13.11 0 34 .423 -1.453 .184 
 
2.9.1 Sex of Participants 
Of the sample, six were women and four were men. A chi square test was 
performed and identified that there was no sex bias, X2 (1, N=10)= .400, exact 
sig. = .527.   
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2.9.2 Birth Country and Language  
The sample consists of people who were not born in the UK, and some who had 
English as a second or additional language. There were six participants who 
spoke English as a first language and were born in the UK. Participants spoke 
English as an additional language (Romanian = 1), as a second language, 
(Ethiopian = 1), as a third language (Lebanese = 1), or were born in the UK and 
spoke English as a third or fourth language (British Pakistani = 1).  
 
As neuropsychological tests are normed on people who speak English as a first 
language, it was important to examine if there were any differences in 
performance in the tests that were administered with participants. A Mann-
Whitney U test did not find any significant differences in the scores on the 
cognitive tests between those who spoke English as a first language and those 
who did not. This would indicate that language did not significantly impact the 
performance of the study participants.  
 
2.9.3 Employment status 
From the sample, five people were looking for work and five were employed in 
some capacity, which captures a social inequality in the group. 
 
2.9.4 Comorbidities 
With a diagnosis of T2DM, you are at risk from several other conditions that can 
interact with and complicate the pathogenesis of T2DM. Some participants had 
CVD (N=1), Hypertension (N=2) that was being controlled with medication and 
Retinopathy (N=1), which was also being treated. Conditions of this nature would 
be expected in a population of people with T2DM.  
 
2.9.5 Diabetes-related health indicators 
All participants have been diagnosed diabetes, which is a pre-requisite for 
attending the clinic. They were also required to get their blood tested for clinically 
relevant markers (e.g. Hba1c, Lipid profile). 
 
2.9.5.1 Hba1c: was obtained from medical notes with participant’s permission 
and this was recorded for all study participants. People with T2DM are advised to 
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set individual targets with their healthcare professionals about what level Hba1c 
they should maintain. But as a guideline, patients are advised to keep blood 
sugars below 48mmol/mol (National Institute for Health and Care Excellence, 
2016b). Of the study participants, one person had their blood glucose below this 
level. Therefore, of the study sample, the majority of people did not have ‘optimal 
control’ of their T2DM. 
 
2.9.5.2 Lipid profile: this comprises four figures: total cholesterol, HDL, LDL and 
TG. This was also obtained for all participants.  For one participant, a partial lipid 
profile was collected due to problems with the blood test at the time. 
Targets for optimum lipid control in someone with diabetes should be total 
plasma cholesterol <4.5-mmol/L (~175 mg/dL) and LDL <2.5mmol/L 
(~100mg/dL), at least. Whilst no targets are set for HDL and TG, HDL 
concentrations in men <1.2mmol/L (~40mg/dL) and women <1.2mmol/L 
(~40mg/dL) and TG >1.7mmol/L (~150mg/dL) would be an indication of 
increased CVD risk (Graham et al., 2007).  
 
Of the study participants, eight had levels of total cholesterol that were optimum, 
nine had optimum LDL, and three people in the sample were at increased risk of 
CVD, based on the concentration of their HDL and TG levels. 
 
2.9.5.3 Duration of diabetes: was recorded in months for all study participants. 
This is related to existing research that suggests the longer that someone has 
had diabetes, the more likely they will show complications of the condition. 
 
2.9.6 Cognition related health indicators 
2.9.6.1 Head injury: Of the study population, two people had suffered a head 
injury in the past, and both had received treatment for this. Due to the low 
numbers in the study population, no further analysis was performed to compare 
these two participants for any differentiating factors from the rest of the sample.  
 
No one in the population sample had a history of severe mental illness, epilepsy 
or muscular sclerosis. 
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3. RESULTS 
 
 
3.1 Exploratory Data Analysis  
 
For the sample, descriptive statistics were used to look at the mean, SD and data 
distribution of the demographic, T2DM and age-scaled scores for the cognitive 
tests. The domains examined were optimal ability, verbal attention, processing 
speed, executive function, verbal and visual immediate and recall memory, and 
verbal and visuo-spatial. In addition, the data was scrutinised for skewness, 
kurtosis and the Shapiro-Wilk statistic was used to see if the data satisfied the 
conditions for parametric normality.  
 
Skewness shows shape and should be less than 1; kurtosis indicates the 
peakness and should be no greater than 3, and a significant Shapiro-Wilk (p<.05) 
would indicate the data does not have a normal curve (Field, 2013). The 
exploration of data showed that most of the demographic variables in the study 
were mostly normally distributed, as indicated in Table 1. However, participant 
test scores were not normally distributed and there were a small number of 
participants. This would indicate that the data does not satisfy assumptions for 
linear statistics and non-parametric tests should be used.  
 
3.2 Analysis of Cognitive Function 
 
As neuropsychological tests measure performance in areas that change with age, 
scaled scores were used, which are age adjusted. Descriptive statistics were 
carried out, and the sample was compared to the putative norm by using a 
Komogrov-Smirnov (K-S) test. This test looks at how much sampled scores vary 
from normally distributed scores with the same mean and SD (Field, 2013). If 
results are significant, we may conclude that the distribution in the sample is 
significantly different from a normal distribution. This compared the performance 
of participants on cognitive tests to normative data (M=10, SD=3), which applies 
to subtests taken from the TOPF, WAIS, WMS and DKEFS. 
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Visual inspection of the data in Table 2 shows that from the study sample, there 
are no obvious outliers or areas of difficulty and most data is distributed about the 
mean. The lowest scores seem to be for Number-Letter Switching and highest for 
switching output and accuracy.  
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Table 2  
Descriptive and Distribution Statistics for Participants’ Test Scores 
Subtests (SS) Mean SD Min Max Skewness Kurtosis Shapiro- 
Wilk 
Optimal Ability  9.40 2.503 4 12 -1.048 1.335 .127 
Verbal Attention        
Digits Forward  9.40 5.125 3 18 .726 -.797 .129 
Digits Backward  8.80 3.155 6 16 1.529 2.155 .036 
Digits Sequencing  9.00 2.055 5 11 -1.057 .386 .040 
Digits Span  8.50 3.837 4 16 1.040 .411 .168 
Processing Speed        
Colour Naming  8.20 2.573 4 12 .213 -.513 .574 
Colour Word  9.20 3.048 3 14 -.708 1.092 .600 
Visual Scanning  9.60 2.171 7 13 .319 -1.343 .321 
Number Sequencing  8.00 4.295 2 13 -.042 -1.862 .128 
Letter Sequencing  9.20 3.795 2 14 -.727 -.218 .573 
Digit Symbol Coding  8.50 2.415 6 13 .917 -.147 .091 
Executive Function        
Letter Fluency  9.90 5.065 3 19 .535 -.588 .663 
Category Fluency  11.80 4.756 6 18 -.077 -1.929 .143 
Switch Output  12.30 4.877 3 18 -.622 -.335 .308 
Switch Accuracy  12.70 3.945 5 17 -.793 -.088 .251 
Inhibition Scaled  9.80 3.084 5 14 -.505 -.681 .481 
Inhibition Switching  8.50 4.197 1 13 -.879 -.163 .159 
Number Letter  7.20 4.104 1 12 -.432 -1.598 .187 
Learning & Memory - Verbal/Visual 
Story Immediate  10.40 1.897 8 14 .498 -.104 .573 
Story Delayed  9.70 2.003 6 13 -.523 .614 .351 
Visual Immediate  9.30 3.653 3 14 -.522 -.927 .577 
Visual Delayed  10.40 2.951 6 16 .320 .198 .912 
Verbal & Visuo-Spatial 
Similarities   8.70 3.020 2 11 -1.486 1.475 .004 
Block Design  8.50 2.369 6 12 .251 -1.839 .086 
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From the inferential statistics in Table 3, there seems to be a similar pattern: 
Switching Output and Accuracy (Executive Function) is a relative strength within 
the population sample, whereas Digit Span and Digit Symbol Coding (Attention 
and Processing Speed) were relative weakness across the studied sample. 
 
This pattern of relative weakness is partly in keeping with existing research in the 
area, which suggests that processing speed and attending to information may be 
impacted (Manschot et al., 2006). However, the pattern of relative strengths for 
EF is not something we would predict in a sample of people with T2DM (Vincent 
& Hall, 2015).  
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Table 3  
Participant data for Neuropsychological Tests compared to Normative Data 
Subtests 
SS 
Mean of SS of 
Test 
SD of SS 
of Test 
Kolmogrov-
Smirnoff Z 
p 
Optimal Ability 100 15 .798 .547 
Verbal Attention     
Digits Forward 10 3 1.293 .071 
Digits Backward 10 3 1.099 .179 
Digits Sequencing 10 3 1.168 .130 
Digits Span 10 3 1.362 .049 
Processing Speed     
Colour Naming 10 3 1.099 .179 
Colour Word 10 3 .852 .462 
Visual Scanning 10 3 .632 .819 
Number Sequencing 10 3 1.293 .071 
Letter Sequencing 10 3 .660 .776 
Digit Symbol Coding 10 3 1.362 .049 
Executive Function     
Letter Fluency 10 3 .798 .548 
Category Fluency 10 3 1.293 .071 
Switch Output 10 3 1.415 .036 
Switch Accuracy 10 3 1.712 .006 
Inhibition Scaled 10 3 .481 .975 
Inhibition Switching 10 3 .632 .819 
Number Letter 10 3 1.14 .167 
Learning & Memory - Verbal/Visual 
Story Immediate 10 3 .798 .547 
Story Delayed 10 3 .852 .462 
Visual Immediate 10 3 .660 .776 
Visual Delayed 10 3 .632 .819 
Verbal & Visuo-Spatial 
Similarities  10 3 1.168 .130 
Block Design  10 3 1.079 .194 
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3.3 Analysis of Contrast to Estimate of Premorbid Functioning 
 
Tests of premorbid functioning are used to estimate examinee’s optimal ability 
prior to the onset of illness. From the literature review, there was a dearth of 
research that applied this method. As such, we wanted to explore the relationship 
between cognitive tests and estimates of premorbid functioning using the TOPF 
(see Table 4). By comparing the performance on the TOPF to participant’s 
current scores of cognitive tests, we estimate decline in areas of cognitive 
functioning.  
 
From visual inspection of the data in Table 4, it would indicate from the mean 
scaled scores that the participants have not shown a significant change or 
‘impairment’ (Means=>3) for any test. Interestingly, there is an improvement in 
switch accuracy scaled score compared to the TOPF scaled score (M=-3.30) that 
would indicate an improvement in optimal ability, which is not the direction of the 
relationship that would be expected. As this was the only variable to show 
significant change, no further analyses were carried out comparing the TOPF to 
other tests.  
 
  48 
Table 4  
TOPF Compared to Other Scaled Scores from Neuropsychological Tests. 
TOPF minus SS Mean SD Min Max Skewness Kurtosis 
Digit Span Forwards .00 4.944 -7 6 -.124 -1.761 
Digit Span Backwards .60 2.503 -4 3 -.759 -.746 
Digit Span Sequencing .40 2.011 -4 3 -.893 1.939 
Digit Span Overall .90 3.247 -4 4 -.619 -1.316 
Colour Naming 1.20 3.490 -3 8 1.007 .260 
Word Reading .20 2.658 -2 6 1.285 1.297 
Visual Scanning -.20 3.521 -6 5 -.270 -.448 
Number Sequencing 1.40 4.671 -6 10 .337 -.073 
Letter Sequencing .20 4.050 -4 10 1.751 3.583 
Digit Symbol Coding .90 2.961 -5 5 -.745 .314 
Letter Fluency -.50 4.116 -9 6 -.544 1.365 
Category Fluency -2.40 3.950 -7 3 .075 -1.896 
Switch Output -2.90 4.864 -11 6 .170 .154 
Switch Accuracy -3.30 4.001 -10 4 .158 .155 
Inhibition Scaled -.40 2.836 -5 4 .326 -.110 
Inhibition Switching .90 3.635 -6 7 -.351 .662 
Number Letter 2.20 3.521 -2 8 .423 -.912 
Story Immediate -1.00 3.399 -6 4 -.255 -1.188 
Story Delayed -.30 3.592 -6 5 -.486 -.306 
Visual Immediate .10 3.665 -4 7 1.170 .373 
Visual Delayed -1.00 3.055 -6 4 .088 -.551 
Similarities .70 1.636 -2 3 -.350 -1.093 
Block Design .90 2.807 -5 5 -.890 1.309 
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3.4 Relationship between Diabetes-Related Health Indicators 
 
Due to the small sample size, non-parametric tests were used to look at the 
correlation between different diabetes-related health indicators: duration of 
diabetes, hba1c and lipid profile (total cholesterol, HDL, LDL and TG). There 
were no correlating variables apart from TG and HDL (r=-.795, p<.01).  
 
3.5 Relationship between diabetes markers and cognitive function 
 
Non-parametric tests were also used to look at the correlation between cognitive 
function (as measured by the scaled scores on the tests) and diabetes clinical 
information: Hba1c, lipid profile, duration of diabetes. A Spearman’s-Rho 
correlation was selected to explore the relationship and relevant statistics are 
detailed below. 
 
3.5.1 Hba1c 
Hba1c was correlated with a subtest from the learning and memory domain in a 
visual task, Visual Immediate (r=-.738, p<.01) and verbal-spatial, Similarities (r=-
.623, p<.05).  
 
3.5.2 Lipid profile 
 
3.5.2.1 Total cholesterol (chol): was correlated with several variables: verbal 
attention, specifically Digit Span Forward (r=.746, p<.01), Digit Span Sequencing 
(r=.558, p<.05) and Digit Span (r=.603, p<.05) subtests; executive function, 
specifically Switch Output (r=.630, p<.05), Switch Accuracy (r=.674, p<.05), 
Inhibition (r=.650, p<.05), Inhibition Switching (r=.650, p<.05) and Number Letter 
Switching (r=.624, p<.05) subtests; verbal learning and memory, Visual 
Immediate (r=.554, p<.05) subtests; and visuo-spatial construction (r=.724, 
p<.01). 
 
3.5.2.2 HDL: was correlated with processing speed in the subtest Word Reading 
(r=-.745, p<.01). 
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3.5.2.3 LDL: was correlated with EF, specifically the Inhibition subtest (r=.646, 
p<.05). 
 
3.5.2.4 TG: was correlated with processing speed, in the subtest Number 
Sequencing (r=-.583, p<.05). 
 
Overall, the Spearman’s-Rho indicated a possible relationship between health 
outcomes related to diabetes and cognitive function, although this is exploratory 
in nature and should be interpreted with caution.  
 
3.6 Summary of relationship between diabetes clinical markers and 
cognitive function 
 
With regards to biological markers in the sample, there appeared to be 
relationships between different factors related to diabetes: Hba1c was negatively 
correlated with learning and memory, and verbal-spatial tasks, where the higher 
the Hba1c level was, the lower the performance on the tasks; total cholesterol 
was positively correlated with tests in all domains apart from processing speed, 
with a higher cholesterol level being associated with a higher score on some 
subtests; as HDL and TG affect and are affected by levels of cholesterol in the 
blood, they were also negatively correlated with tests that measure processing 
speed.  Whilst LDL was significantly correlated with Inhibition, the reason for this 
is unclear but it is noted there was data missing for one participant for this value, 
which may have adversely affected the correlation. 
 
3.7 Case Series Analysis 
 
The sample of participants differed across many variables, such as level of 
education, first language and duration of the condition. As a result, the individual 
profiles of participants were examined to explore any patterns in individuals, 
taking into account demographic factors and any concurrent conditions.  
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3.7.1 Participant One 
Participant one was a 32-year old female who was currently unemployed but 
educated to degree level. She was originally from Romania and spoke English as 
an additional language. She was diagnosed with diabetes and hypertension in 
March 2016; her Hba1c was 61% mmol, Lipid: Total cholesterol (chol) 3.9% 
mmol;  HDL 0.7% mmol; LDL 2% mmol; and TG 2.7% mmol. 
 
 
 
Figure 1. Scaled test scores for participant one. 
 
As indicated in Figure 1, the participant showed relative strength in the domains 
of Executive Function (EF), specifically Switch Output and Accuracy and 
Learning & Memory, specifically Story Immediate. There were some relative 
weaknesses in several domains:  in EF there were particular weaknesses in 
Number-Letter Switching; in Learning & Memory, there was a substantial change 
between scores of Story Delayed and Immediate; and finally, there were low 
scores in Block Design in the domain of visuo-spatial construction. Most scores 
were distributed around the Average-Low Average range, and no scores were 
categorised as ‘impaired’. Her Optimal Ability score did not hold much power as a 
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predictor of the rest of her scores. Whilst this participant spoke English as an 
additional language, as she has studied to undergraduate level, it is unlikely to 
have negatively impacted her performance on this test of reading ability. This 
participant was being treated for low mood in the clinic, which may partially 
account for the variability in her scores due to possible psycho-motor slowing in 
tasks that require attention and mental manipulation.  
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3.7.2 Participant Two 
Participant two was a 51-year-old male who was self-employed and identified as 
British Indian. He spoke English as a first and only language. He had been 
diagnosed with diabetes in December 2015 and had some ulceration in his feet 
for which he was seeing a podiatrist at the clinic. He was managing his diabetes 
with diet and exercise, and took no diabetic medication. His most recent Hba1C 
was 89.1% mmol/ml and Lipid: Chol 4.4% mmol;  HDL 0.7% mmol; LDL 2% 
mmol; and TG 2.7% mmol. 
 
 
 
Figure 2. Scaled test scores for participant two. 
 
As seen in Figure 2, the participant showed a strong profile overall, with relative 
strengths in verbal attention, specifically the Digits Forward subtest and EF, 
specifically the Category Fluency subtest. There were relative weaknesses in this 
participants profile in the learning and memory domain, specifically the Visual 
Immediate subtest but otherwise, most of his skills were intact. The TOPF did not 
seem to be a good indicator of his optimal ability relative to the rest of his scores.  
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3.7.3 Participant Three 
Participant number three was a 49-year-old Lebanese lady, who spoke English 
as a third language after Arabic and French. She was not working and was 
educated to college level. She had been diagnosed with diabetes in 2003: her 
Hba1c was 101% and Lipid profile: Chol 5.5% mmol; HDL 1.0% mmol; and TG 
4.8% mmol. It was not possible to get LDL levels because of a problem with the 
most recent blood test.  
 
 
 
Figure 3. Scaled test scores for participant three. 
 
Figure 3 shows that this participants profile was mixed overall, and most of her 
scores were in the Average range. There were some relative strengths in EF, 
specifically the Switch Accuracy subtest and some relative weaknesses and 
potential decline in processing speed, specifically the Number Sequencing and 
Letter Sequencing tests. Processing speed is an area that might typically be 
affected in people with diabetes, and compared to other domains that were tested 
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it is the most impaired. This profile shows us that this participant’s optimal ability 
is a useful score to measure against her performance across the rest of the tests. 
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3.7.4 Participant Four 
Participant four was a 58-year-old man from Ethiopia, who spoke English as a 
second language. He was trained as an electrician but was between jobs at the 
time of testing. He had suffered a severe head trauma in 2001 and was 
hospitalised for two weeks for treatment. Participant four was diagnosed with 
diabetes in 2008: his Hba1c was 60.7% mmol and Lipid profile: Chol 3.6% mmol;  
HDL 0.7% mmol; LDL 1.5% mmol; and TG 3.1% mmol. 
 
 
 
Figure 4. Scaled test scores for participant four. 
 
As seen in Figure 4, this participant’s scores were also quite varied. There are 
relative strengths in learning and memory, specifically Story Immediate and 
Visual Delayed and some aspects of processing speed on the Word Reading 
subtest. However, there were also some relative weaknesses and possible 
decline in processing speed from the Number Sequencing test and also in 
executive function, Number Letter Switching. In addition, for the tests of verbal 
attention, it is unusual for someone to get a lower scaled score for Digits Forward 
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compared to Digits Backward or Sequencing. This discrepancy was attributed to 
a better understanding of the test rubric later on. The profile for participant four 
shows us that their optimal ability is a useful score to measure against his 
performance across most of the tests. Considering that he spoken English as a 
second language, the impairment seen in some of the performances was 
interesting:  although this was interpreted as a misunderstanding of the tasks, it 
was recommended that if doing several tasks at once, or holding things in mind 
became more difficult for participant four, that the cognitive assessment be 
repeated via the GP. 
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3.7.5 Participant Five 
Participant five was a 30-year-old British female graduate. She was unemployed 
at the time of testing. Participant 5 had experienced a subcortical haemorrhage, 
which had been treated successfully. She had been diagnosed with diabetes in 
2014. Her Hba1c was 76% mmol and Lipid profile: Chol 5.6% mmol;  HDL 1.5% 
mmol; LDL 3.6% mmol; and TG 1.3% mmol. 
 
 
 
Figure 5. Scaled test scores for participant five. 
 
Figure five shows intact skills in executive function, with particular strengths in 
Category Fluency, Switch Output and Accuracy and unaffected skills in learning 
and memory. For the domains of verbal attention and processing speed, there is 
less of a discernible pattern: there are relative weaknesses across all tests in 
Digit Span and also Colour Naming and Digit Symbol coding. This participant’s 
scores for the TOPF did not offer much predictive power of their optimal ability 
across the administered tests, for which there was no distinctive pattern.   
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Although overall, most of this participant’s profile was in the High Average range, 
there was considerable variability. The participant was seeing a psychologist for 
difficulties with low mood and anxiety at the time of testing, which could account 
for this. However, the recommendation was to monitor any concerns around 
cognitive function and this patient could be re-tested in the future.   
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3.7.6 Participant Six 
Participant six was a 45-year-old British male. He worked as a chess coach and 
was educated to college level. Although he had been diagnosed in January 2016, 
he was being treated for retinopathy and treated by consultant and nurse 
specialist. Participant 6’s Hba1c was 38.8% mmol and Lipid Profile: Chol 2.2% 
mmol;  HDL 1.3% mmol; LDL 0.6% mmol; and TG 0.7% mmol. 
 
 
 
Figure 6. Scaled test scores for participant six.  
 
As seen in figure six, participant six’s performance showed impairment relative to 
his optimal ability across most of the scores on his test profile. His score on the 
TOPF indicates he has higher than average premorbid functioning. He did obtain 
relatively strong scores in some tests of executive function, namely Letter 
Fluency and Category Fluency. However, some other test scores in executive 
function showed a deficit, such as in the Inhibition and Inhibition Switching 
subtests. In addition, this weakness was also seen in the visuo-spatial 
construction test, Block Design. In summary, whilst participant six scored within 
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the Average range overall, there are some aspects of his profile that would be 
typical of someone with diabetes that were affected cognitively, especially relative 
to his optimal ability which tended to be higher than most of his test scores.   
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3.7.7 Participant seven 
Participant seven was a 54-year-old British male who worked as a painter and 
decorator, and attended school until aged 15. He was diagnosed with Diabetes in 
2007. His most recent Hba1c was 95% mmol and Lipid profile: Chol 3.9% mmol;  
HDL 1.0% mmol; LDL 2.3% mmol; and TG 1.4% mmol. 
 
 
 
Figure 7. Scaled test scores for participant seven. 
 
From figure seven, we can see this participant scored quite low on the TOPF. 
Most of the scores were variable although he had relatively intact skills for most 
domains, and verbal & visuospatial skills were a relative weakness. The majority 
of domains also show areas of relative strengths: attention - Digit Span Forward 
and Digit Span Sequencing; processing speed - Visual Scanning, Number 
Sequencing, Letter Sequencing and Digit Symbol Coding; executive function - 
Category Fluency, Switch Output and Accuracy and Inhibition Switching; and 
verbal learning and memory, Story Immediate and Story Delayed. This would not 
be a typical profile you may expect of someone with T2DM, especially 
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considering the high Hba1c they had, and how long they had the condition. 
Furthermore, this would indicate that optimal ability does not hold much predictive 
power for this participant in assessing potential impairment as a result of having 
diabetes.  
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3.7.8 Participant Eight 
Participant Eight was a 50-year-old British born Asian female, who spoke English 
as an additional language alongside Bengali and Urdu. She completed one year 
of college and was employed as a catering assistant in a school. She had 
hypertension, which was being treated. She had a heart attack in 2015 and was 
being monitored for possible kidney problems. Her diabetes was diagnosed in 
2005. Her Hba1c was 70% mmol and Lipid Profile: Chol 3.3% mmol;  HDL 1.0% 
mmol; LDL 2.3% mmol; and TG 2.8% mmol. 
 
 
 
Figure 8. Scaled test scores for participant eight.  
 
Figure 8 shows us that this participant had a varied profile across all domains. 
Compared to her test of optimal ability, it may indicate there have been relative 
declines across all domains apart from verbal and visuospatial. There was also 
some relative strength in processing speed, namely Colour Naming, and in 
executive function, specifically Inhibition. However, compared to participant 
eight’s score in the TOPF, all scores were mostly below what would be expected 
based on her test of optimal ability, particularly her scores in verbal attention. 
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This may indicate some impairment relative to premorbid functioning, although 
some skills across the sequelae seem to be preserved.  
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3.7.9 Participant nine 
Participant nine was a 55-year-old British female who was employed as a 
medical secretary, and completed her O-levels. She was diagnosed with diabetes 
in 2001. Her Hba1c was 63.9 and Lipid profile: Chol 4.4% mmol;  HDL 1.0% 
mmol; LDL 1.5% mmol; and TG1.9% mmol. 
 
 
 
Figure 9. Scaled test scores for participant 9. 
 
From figure nine, this participant achieved high scores in verbal attention in the 
Digits Forward subtest and she performed well in most tests of executive function 
but particularly in Letter Fluency.  Many of her lower scores were in tests that 
measure processing speed or in immediate memory. However, these scores 
were relative to her scores of optimal ability and were equal or less than two 
standard deviations away than the TOPF score. The scores participant nine 
obtained show some aspects of a distribution that may be expected in people 
with T2DM e.g. lower in processing speed but due to the variability across all the 
domains, this could not be concluded with any degree of certainty. In addition, 
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this participant has done better than her score of optimal ability in the majority of 
the subtests administered across different domains.  
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3.7.10 Participant 10 
Participant 10 was a 32-year-old British female. She was college educated and 
was looking for work as she had just moved into the area. Her diabetes was 
diagnosed in 2015 and her Hba1c was 106% mmol and Lipid Profile: Chol 3.7% 
mmol;  HDL 1.7% mmol; LDL 1.4% mmol; and TG 1.3% mmol. 
 
 
 
Figure 10. Scaled test scores for participant 10. 
 
Overall, the cognitive profile for participant ten is typically in the Below Average or 
Impaired range. Whilst this is relative to her optimal ability scaled score, which 
was very low, there are some areas of relative strength but also weaknesses. 
This participant scored well in one test of processing speed, Visual Scanning, 
tests of learning and memory, specifically Story Immediate and Story Delayed, 
executive function in the Switch Accuracy subtest, and visuo-spatial construction, 
in Block Design. The areas that were most impaired were in tests of executive 
function, Letter Fluency, Inhibition Switching and Number-Letter Switching, and in 
verbal construction, Similarities.  Interestingly, there seems to be no discernible 
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pattern about where this participants strengths lie, for example, there were 
relative strengths and weaknesses of tests of both language and visual skills. 
Typically, you may expect someone to perform well in one area and not in the 
other, rather than performing well and not so well in both. This may be explained 
in part by the life stresses that this participant was experiencing at the time of 
testing that were numerate and lengthy.  I note she suffered a fractured skull 
aged five and said she had been diagnosed with dyslexia as a child.  
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3.8 Summary of Case Series Analysis 
 
The exploration of the variables within the participant sample generates a 
different perspective on the potential impact of diabetes-related markers, as well 
as looking at patterns in individuals who were tested.  
 
3.8.1 Comparison to TOPF 
Overall, most participants scored in the average range or lower for the TOPF, but 
relative to this score, had very varied profiles across the range of subtests. 
Therefore, the scores on the TOPF may not be a valuable test by which to 
measure potential decline in T2DM. 
 
3.8.2 Comparison to other group sample findings 
Overall, the group sample showed that some tests of executive function were a 
relative strength and that some scores of attention and processing speed were a 
relative weakness. Looking at the individual case series, there were some 
participants that fitted with this profile but the majority did not. As described 
above, there was a lot of variability across the sample, showing patterns that 
were not easy to compare between participants. Yet, one aspect was discernible: 
most participants seemed to show some strength overall or relative to their 
optimal ability score in executive functioning, and specifically in the switch output 
task. This could indicate an issue with this particular task. On the whole, there 
was a lot of variability between and within the participant scores on the cognitive 
tests.  
 
3.8.3 Summary 
The case series analysis should be interpreted with caution, due to the small 
number of participants and the lack of statistical power this has. Furthermore, 
there are a number of factors that could have affected the performance on tests. 
For example, the clinical psychologist in the service was seeing three of the 
participants for difficulties with low mood and/or anxiety. In addition, one person 
had to be referred for urgent mental health assessment from testing, due to 
thoughts of suicide, which was picked up from the BDI. As difficulties like low 
mood and anxiety can impact on the speed in which we process information 
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(White, Myerson, & Hale, 1997), this can affect cognitive function overall (Hart & 
Kwentus, 1987; Ebmeier, Donaghey, & Steele, 2006). In addition, high levels of 
cholesterol are known to improve learning and memory (Schreurs, 2010) and so 
higher scores on some tests, may be indicative of this rather than intact function 
in some domains. Therefore, because of the complex interplay of the 
comorbidities in this population, we cannot attribute better or poorer performance 
on some tests to diabetes or factors associated with diabetes. 
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4. DISCUSSION 
 
 
4.1 Summary 
 
It has been established that diabetes can affect cognitive function, especially in 
older adults and the longer that one has the condition. Diabetes has become a 
global epidemic in health and economic terms. As such, great lengths are being 
taken to examine how diabetes can be stopped from progressing to the extent 
where it entails excessive treatment costs and causes premature death. Despite 
extensive research in the area, there is little consensus about the cognitive 
sequelae that are affected. With T2DM becoming the most common diabetes 
phenotype in children and adolescents in some parts of the world (Ke et al., 
2015), concerns have been raised about how a condition of this nature will 
progress in people so young. This study set out to look at the potential impact of 
diabetes on cognitive function in younger adults, to explore whether the potential 
cognitive impact, is comparable in this population.  
 
Ten individuals aged between 30 and 55 with T2DM were recruited from a 
London diabetes clinic and completed a battery of measures: this included 
demographics, medical history, health in the diabetes context, tests of cognitive 
function and measures of mood. Scores were closely examined for the 
relationships between cognitive variables, comparing the obtained scores to 
normative means and standard deviations. Finally, each participant was 
individually examined for his or her comparability to the group sample.  
 
4.2 Population Demographics 
 
The sample constituted a group of people with T2DM, of different ages, and each 
person was at a different stage of the condition, including the duration of their 
diabetes and how they were managing the condition e.g. dietetic input, type of 
medication, regular exercise. One person in the group had managed to keep their 
Hba1c level within an optimum range and others had comorbid conditions as well 
as their diabetes, which would suggest that any results should be interpreted 
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carefully as they may not be generalisable to other groups of people with 
diabetes.  
 
Correlation analysis showed a relationship between Hba1c and tests of learning 
and memory and verbal-spatial construction, and cholesterol with a multitude of 
cognitive tests. Interestingly, no other diabetes-related health indicators were 
correlated with the cognitive tests, which is useful information considering the 
level of relatively good health within the sample.  
 
4.3 Areas of Research Interest  
 
4.3.1 Optimal Ability 
The estimated optimal ability of the group was mostly in the average range. 
Although the sample was split 50:50 between people who spoke English as a first 
or a second or additional language, there were no obvious effects of language on 
performance. 
  
When comparing optimal ability to health indicators related to diabetes, the TOPF 
was not correlated with values obtained from participants for Hba1c or 
cholesterol, nor any demographic aspects of the condition e.g. age, suggesting it 
is a robust measure in this sample.  
 
As tests of optimal ability have not been used routinely in research into diabetes 
and cognitive function, the scores in this domain were compared to the other 
domains included in the test battery. No tests showed a significant impairment 
compared to scores of optimal ability. However, one test of executive function 
significantly improved following testing, indicating a possible anomaly with this 
sample.  
 
4.3.2 Diabetes-related health indicators and cognitive function 
Several variables related to diabetes were recorded: Hba1c, also known as the 
average glucose concentration in the blood over the last three months; lipid 
profile, which included total cholesterol, HDL, LDL and TG; and duration of 
diabetes. Only one of the participants had their levels of Hba1c within the 
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optimum range, but the majority of the sample did have lipid profiles within the 
recommended parameters.  
 
Hba1c: was negatively correlated with tests of learning and memory. This may 
indicate that cognitive function can be affected by levels of glycated haemoglobin. 
This is consistent with research in the area, which suggests that higher levels of 
Hba1c were associated with worse cognitive function, accelerated memory loss, 
and overall decline (Yaffe et al., 2012; Marden et al., 2017).  
 
4.3.2.1 Total cholesterol: was the variable related to diabetes, which showed the 
most significant values, but they were all positively correlated. Higher levels of 
total cholesterol were associated with higher scores on tests of attention, 
executive function, visuo-spatial construction and learning and memory. This 
could suggest that higher levels of cholesterol can protect cognitive function. 
Previous literature in the area has indicated that cholesterol can influence a 
series of learning and memory tasks but the nature of that influence is difficult to 
understand (Schreurs, 2010). However, whilst controversial, there is some 
evidence to suggest that higher cholesterol can improve cognition in certain 
tasks. Indeed, higher total cholesterol in mid-life is linked to poorer cognitive 
performance later in life but, if cholesterol levels lower after mid-life, this may 
indicate poorer cognitive status (Solomon et al., 2009). As noted previously, the 
relationship between cholesterol and cognition is not well understood, and any 
supporting inferential statistics from this study should be interpreted with caution. 
 
4.3.2.2 HDL: showed a significant negative correlation with one test in the domain 
of processing speed (Word Reading).  This indicates that lower HDL was 
associated with higher scaled scores on this test, which measures visual 
scanning and verbal output. Also known as ‘good’ cholesterol, lower levels of 
HDL would not be expected to correlate with tests of processing speed in this 
direction. As there is only one test that shows this relationship, it may not be 
useful to infer too much from this result. This is discussed further in limitations 
and recommendations.  
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4.3.2.3 LDL: positively correlated with one test of executive function, Inhibition. 
Whilst higher levels in the sample are related to better performance on this 
specific test, usually high levels of LDL are associated with higher risk of 
atherosclerosis or the build up of plaque in your arteries. Therefore, this 
correlation is not in the direction anticipated.  
 
4.3.2.4 TG: was found to negatively correlate with a test of processing speed, 
Number Sequencing. For this sample, the lower the measured value of TG, the 
higher the obtained score in Number Sequencing. As TG are a type of fat in the 
blood, it is recommended that this is kept low. The relationship between the 
measured variables in this sample is in the direction predicted.  
 
4.3.3 Relationship of demographic factors with cognitive function 
The final area of interest was examining whether any areas of ‘impairment’ were 
related to demographic variables, such as duration of diabetes or age. However, 
by using scores of optimal ability as an indicator of impairment, there were no 
signs of change e.g. a lower score on subtests compared to scores of optimal 
ability. Therefore, no further statistical tests were undertaken to explore these 
variables further. 
 
As mentioned previously, there was a significant improvement from scores of 
optimal ability compared to the scores obtained in Inhibition Switching. It is 
unusual to make an improvement of this nature but methodologically, there did 
not seem to be any errors in administration. This is discussed further in limitations 
and recommendations. 
 
4.4 Case Series Analysis 
 
From examining the individual profiles, the majority of participants did not follow 
the pattern of the group level analysis.  
 
4.4.1 Tests of premorbid functioning 
There was inconsistency in how useful the TOPF was as an estimator of 
premorbid ability in this sample: for the majority of participants it held little 
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predictive power. But for some participants it did seem to be an indicator of some 
kind of change relative to their TOPF score. However, because of the small 
sample, there were myriad different variables within that sample that could not be 
statistically controlled for, and it would be difficult to generalise beyond this 
sample.  
 
4.4.2 Cognitive function  
The observed distributions at a case level were also very varied and it was 
difficult to discern patterns between the cognitive test scores within the battery 
and also to the measured diabetes variables. 
 
Examining participant data individually, most did not show the pattern of relative 
weakness in the cognitive domains that were analysed at the group level: namely 
in attention and processing speed.  
 
However, executive function was an area that many participants performed well 
in. It could be that for this particular group there was something unique about 
those that were sampled, for example, being able to fit in testing around work 
commitments (for those that were employed) and remembering to come at the 
agreed time, as there were only a couple of issues during recruitment. Therefore, 
this could indicate people were already able in the domain of EF. Alternatively, 
people that chose and were able to attend testing may have been self-selecting, 
in that they were aware of their skill set and were motivated to attend an 
assessment.  
 
4.4.3 Comparisons to previous work in the field 
These findings are somewhat at odds with existing literature into the area, as 
most literature suggests that even in younger adults, there can be signs of 
cognitive impairment early in the pathogenesis of diabetes (Ruis et al., 2009). 
Some research indicates that in people with T2DM there are observable deficits 
across all cognitive domains compared to non-diabetic controls (Monette et al., 
2014). Other research also indicates that there are a variety of domains that are 
affected but typically processing speed (Awad et al., 2004), attention (Manschot 
et al., 2006), and executive function (Mehrabian et al., 2012) may be impacted. 
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However, due to the complexity of diabetes and its co-occurring conditions, 
establishing how T2DM develops universally has been very challenging for 
researchers. Indeed, there has been wide variation in levels of understanding and 
contrasting conclusions made in literature in the area.  
 
For some of the findings that were not related to research questions posed at the 
outset, previous research into cholesterol and memory has controversially found 
that higher levels of cholesterol can actually improve your memory (Schreurs, 
2010). It is hypothesised this is linked to how the cholesterol in the blood 
improves the signals between brain synapses. In the current study, this finding 
was also supported. Whilst the effect size was not large, total cholesterol was 
implicated in better scores on learning and memory across several tests. 
Therefore, we may hypothesise that higher cholesterol seemed to protect 
learning and memory in people with T2DM in this sample.  
 
4.4.4 Application to the research questions: 
In summary, there were three main research questions posed were regarding 
optimal ability, the relationship between clinical markers of diabetes and 
cognition, and whether any impairment would be connected to health indicators 
related to diabetes. 
 
In this particular study, using a test of optimal ability was not statistically useful to 
predict impairment in younger adults with T2DM. However, on an individual basis, 
there was some utility in scores of premorbid functioning as a baseline to 
compare their overall cognitive functioning.  
 
Diabetes-related health indicators were not correlated with values of cognitive 
function in any distinct patterns, although cholesterol did seem to mediate 
cognitive performance more than any other variable.   
 
Finally, there was no cognitive ‘impairment’ observed in this sample and so no 
further analyses were carried out on the data.  
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4.4.5 Summary 
As this study is exploratory in nature, the inferences made should be taken 
lightly. It is not possible to infer if there is a potential window of preservation for 
cognitive function in younger adults with T2DM. However, some productive 
speculation can be made about the relationships between the variables: optimal 
ability may still be a useful predictor of cognitive function in people with T2DM, 
clinical markers of diabetes may mediate performance on cognitive tests, and 
that cognitive impairment could be present in larger sample of younger people 
with T2DM. 
 
4.5 Study Limitations and Recommendations 
 
4.5.1 Limitations 
 
4.5.1.1 Sample size: the main issue for this study is the small number of 
participants that was recruited. Whilst great efforts were taken to promote 
recruitment, it was not possible to recruit as many participants as were intended, 
which was a minimum of 12 and ideally 20. Small sample size increases the 
likelihood of making a type II error (Field, 2013). This smaller sample also meant 
it was not possible to look at within group differences such as age, duration of 
condition, English as a first language or employment status.  
 
4.5.1.2 Lack of a control group in the study design: this meant that it was not 
possible to compare the test performance of the people with T2DM to matched 
controls e.g. spouses, friends, hospital attendees. This would permit a 
comparison of the cognitive function to be made between the groups. Although 
the statistical tests selected were appropriate and accounted for one group for 
comparison, this may have meant that the findings had greater generalisability 
outside of this study.  
 
4.5.1.3 Potential confounders: the clinicians in the service I recruited from had 
one main concern with the recruitment to the study – that it had the potential to 
‘derail’ their interventions, especially if people were difficult to engage. Therefore, 
the clinicians acted as a potential barrier and confounder to recruitment in a non-
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biased way i.e. access to more ‘typical’ patients that perhaps did not regularly 
attend and/or had problems managing their diabetes. In fact, one of the patients 
managed their diabetes so well that from recruiting to testing, had been 
discharged from the service. Therefore, I wonder whether the sample I had was 
less representative of the younger T2DM population in general.  
 
4.5.1.4 Understanding of the test rubric: on the whole, participants seemed to 
understand what was expected of them in each test. There were occasions when 
despite being encouraged to ‘keep going’ or ‘do this task as quickly as you can’, 
the participants preferred to take their time with the tests, especially during tests 
of Executive Function such as the Trail Making Test. This approach seemed to fit 
more with their personal choice to meet the tasks at hand, e.g. being methodical 
and thorough, rather than a measure of their speed at completing the task (or 
lack thereof). 
 
Cognitive tests are normed on Western populations, and some of my sample 
were not born or educated in the West. Cultural and educational differences can 
impact on scores in cognitive tests; therefore, the normative data that was used 
to make comparisons may not be equivalent (Fernandez & Marcopulos, 2008). 
Again, a larger sample size could have controlled for this.  
 
4.5.1.5 Anomaly in test scores: some participants did particularly well in tests of 
executive function, specifically word generation. This was to the extent that 
record sheets were checked on several occasions for any errors of recording. 
The administration instructions were also examined for any possible errors in 
setting up the tasks. However, no errors were found.  
 
4.5.1.6 Generalisability to other populations: due to where the sample was 
obtained in North London, it is questionable if it resembles a representative 
sample of younger age adults with T2DM.  In Camden, the population is relatively 
young and very transient, and people do not tend to stay in the area. As a result, 
the incidence of T2DM is lower than the national average, and lower than the 
London average. A different London borough may have provided a more typical 
cognitive profile than the one obtained.  
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Another question is whether the sample obtained is a self-selected sample of 
people who are more able compared to other younger people with T2DM. For 
example, nearly all the group had finished school and those that had not were 
employed in a long-term capacity. The presence of a control group would have 
been helpful to address queries of this nature.  
 
Finally, there are some cohort differences that mean that measuring cognitive 
functioning in younger adults and then comparing to older adults e.g. people over 
55, may be difficult. For example, the school leaving age in England and Wales 
was raised from 14 to 15 in 1947 (people today aged 70 and over), and the 
compulsory school age became 16 in 1972, raised from 15 (people today aged 
45 and over). The sample looked at people born between 1961 and 1962 
onwards. Whilst it is acknowledged that normed scores are age scaled, there are 
substantial differences in required education that means it could impact on how 
comparisons could be made between these age groups.   
 
4.5.2 Recommendations 
 
4.5.2.1 Implications for existing theories: there is very little research available into 
optimal ability but the current research did fit with a smaller scale study involving 
older people with T2DM and carefully matched controls. Asimakopoulou et al., 
(2002) found there was no statistical difference between these groups on a 
battery of cognitive tests, including a test of premorbid functioning. However, 
larger samples are needed for both this and the afore-mentioned study. 
 
Finding a relationship between Hba1c and tests of processing speed and 
attention is in keeping with existing research into the area (Awad et al., 2004; 
Manschot et al., 2006). I note that this was not a consistent pattern found within 
the data, so more testing would be needed to be establish this link. Furthermore, 
there has been recent research, which has found the connection between 
diabetes and impairment in attention inconclusive (Degen et al., 2016). 
 
The findings related to lipid profile do have implications for the typical health 
messages being relayed regarding cholesterol. For example, we often hear about 
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increasing the good cholesterol in our diets. However, it was total cholesterol that 
mostly showed a significant effect size, not HDL, which is commonly referred to 
as ‘good’ cholesterol. Therefore, there may be grounds to consider this aspect of 
the findings in greater detail.  
 
4.5.2.2 Adaptation of current theories: the findings from the current study have 
limited theoretical implications. Although the conclusions are potentially of 
interest, further research will need to be carried out to establish whether the 
correlations and relationships found can be repeated elsewhere. This would 
enable greater weight to be added to the results, which are at present, 
exploratory in nature.  
 
4.5.2.3 Improving the current study: I would like to recruit more participants, 
aiming for the desired number of twenty participants that I set out to test.  
It could be useful to reduce the number of variables being controlled for and 
reduce the age range. For example, recruiting young people with diabetes e.g. 
aged 35 and under, and use a prospective and longitudinal study, with one 
specific locus, such as processing speed and matched controls. By reducing the 
examined locus, it would speed up testing and make results quicker to score. In 
addition, using the new technology available to administer tests e.g. Q-Interactive 
on tablets, to quicken scoring and sending out results. Furthermore, there is a 
gap in the research into optimal ability and diabetes, as highlighted by the review 
by Wong et al. (2014). It would also be of clinical interest to produce an 
evidenced battery that could be administered quickly, that would not only help 
strengthen any possible link between cognition and diabetes but also be an aid to 
diabetes clinicians.  
 
Whilst the presence of a control group is supposedly a ‘gold standard’ (Goldstein 
& McNeil, 2012), it does not always guarantee appropriate interpretation of 
findings. This can be because the control group differs too widely from the clinical 
sample (Bonato, Sella, Berteletti, & Umiltà, 2012). As such, recruiting a control 
from the clinical participants life would be most suitable, such as a partner, 
relative or friend, to minimise the variability between test and control participants.  
 
  82 
4.5.2.4 Test battery: Psychometric assessments are based on constructs of 
cognition, as we understand it in the contemporary west. Cognitive domains are 
not discreet concepts and interact with each other.  For example, tests of the 
domain of attention are rarely pure, but it is seen as a foundation for all other 
domains of cognition (Hebben & Milberg, 2009). Therefore, adapting the test 
battery may be a useful way to more sensitively test the different domains of 
cognitive function.  
 
4.5.2.5 Cognitive Domains and Test Selection: The selected tests of executive 
function from the battery are regularly used in the literature (Wong et al., 2014; 
Vincent & Hall, 2015). However, it is important to acknowledge that whilst the 
tests selected were done so carefully, if different tests were chosen, it is likely to 
have produced different results. 
  
The TOPF, WAIS-IV and WMS-III are all co-normed together (Holdnack, Zhou, 
Larrabee, Millis, & Salthouse, 2011), which means that the sample norms are 
derived from the same sample of test-takers. This develops more valid and 
reliable test scores and avoids assuming all norms from different test populations 
are equivalent. Whilst there is some contention in the literature about whether co-
norming is required (Rohling et al. 2011), this approach was taken for caution. 
 
Another example of a visuo-spatial test of EF could be the DKEFS Tower Test. 
This test was not selected as another aspect of the rationale for the test selection 
was to choose measures that could form part of a screening battery for clinicians 
from the diabetes team. Therefore, it was felt that tasks using paper-and-pen 
exercises would be more likely to be appropriate for this. 
 
The DKEFS was selected because testing was being done on a presumed 
unimpaired sample. For example, by using the Number-Letter Switching task 
from the DKEFS instead of the Action Program Test from the BADS or the 
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Errands Task, we are testing very specific and different aspects of EF (and are 
not directly comparable). Therefore, we needed very sensitive tests to measure 
the presence of a defect, not the degree of impairment. This is why the DKEFS 
was selected, rather than the BADS, which presumes impairment. Nevertheless, 
it is acknowledged that some of the task focused tests e.g. Errands Task, may be 
more comparable to the tasks expected of someone in managing their diabetes.  
 
Furthermore, the DKEFS subtests selected – Trail Making, Verbal Fluency, and 
Colour Word Test - assess specific aspects of Executive function – namely 
speed, motor and verbal inhibition/switching. It is not sensitive to all aspects of 
EF. Therefore, other tests in the DKEFS could have been selected. Again, 
consideration was given to the time taken to administer the battery. It was 
estimated with the tests already selected from the WAIS, WMS and DKEFS the 
battery would take 90 minutes to administer. Therefore, no additional tests were 
added to minimise the duration of testing due to the demands placed on 
participants. 
 
Putting aside the rationale for selecting the chosen tests within the battery, 
alternative tests that could be used are the Behavioural Assessment of 
Dysexecutive Syndrome (BADS) (Wilson, Alderman, Burgess, Emslie and Evans, 
1996), the DKEFS tower test or the Brixton Spatial Awareness Test (Burgess and 
Shalice, 1997). The BADS would be useful as it may be similar to some of the 
visuo-spatial/sequential tasks required of someone in their diabetes 
management. For example, blood testing before eating and then adjusting your 
food intake or medication regime accordingly. The DKEFS Tower Test or Brixton 
Spatial Awareness Test could assess working memory, and also induction of 
visuo-spatial rules, which could also be comparable to the demands of diabetes 
management. This is because you have to hold several things in mind, and follow 
rules depending on biological markers and instructions given my your clinician or 
pharmacist.  
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4.5.2.6 Statistical tests intended for analysis: at the beginning of the research 
process, the intention was to use General Linear Modelling, to explore a number 
of dependent variables with prediction of relationships for each. As there was no 
control group, this was not possible to use as only people with T2DM were 
assessed. However, future research could consider employing this method.   
 
4.5.2.7 Approach to analysis: In the analysis, it was decided not to converge 
subtests that all tap the same underlying construct to compile an overall score for 
that domain. For example, this would involve combining scores from subtests 
such as Inhibition and Switching, to make a score of ‘Executive function’. 
Approaching analysis this way ensured that collating the tests of a same domain 
did not obscure important differences within the sample. As mentioned 
previously, the intention behind this was it was assumed the population studied 
was unimpaired and so required tests to be sensitive to possible changes. As 
such, a collated score from several subtests for a domain may not have achieved 
this. However, it is useful to address what could be gained by taking such an 
approach and how it may be done.  
 
By converging tests that tapped the same underlying construct, it could have 
evened out individual differences between different tests, and provided a more 
global score in each domain. This may have made the result more reliable as it 
could be compared more easily to other findings regarding the domain of 
executive function, and also be more stable. It would also have had more power 
as only contrasting two or three tests.  
 
To achieve this, two approaches seemed most appropriate: first, within the 
DKEFS tests, you can combine the scores following the manual to obtain an 
average sequencing score, which can be contrasted with inhibition. Secondly, 
you can converge the domains by combining the scaled scores and divide by 
number of tests included in that combination. The first option would offer a 
validated and more specific approach to combining the scores, within the 
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construct of Executive Function; the second, a less robust but more comparable 
approach to other research within the area e.g. those that refer to executive 
function more globally than the approach taken within the thesis.  
 
4.5.2.8 Future research: I would recruit non-diabetic controls to have a group to 
compare the diabetic participants to. Whilst we used a standardised mean and 
SD to compare the results to, which is similar to having a control group, it would 
add a more robust form of data analysis as a recruited group’s mean and SD may 
be different to a set value. 
 
I would also consider using a blood pressure monitoring and blood glucose 
measurement before and after testing. This would require training of the 
researcher or recruitment of a nurse. However, this would add another level of 
external validity to the study. In addition, other similar research has employed 
these methods (Salak Djokić et al., 2015). I would consider matching control 
participants on several characteristics, including premorbid ability.  
 
4.6 Critical review 
 
4.6.1 Personal reflections 
Gaining NHS ethical approval was a difficult task, which took much longer than 
expected. This was in part to being unfamiliar with all the tasks that were 
expected in this process, and relying on fellow trainees, including those on 
different courses to help guide me. There was a change of Dean of the school 
part way through submitting the form for ethics approval and so having to bring 
two people up to speed with the process delayed matters, as did completing it 
over the summer holiday. If I were to approach this process again, I would 
attempt to get ethical approval much sooner and monitor the time when I sent off 
my application more wisely e.g. not over summer. The NHS site where I recruited 
people from took a while to support me with recruitment, and this took a 
considerable amount of liaison with the manager, in-house psychologist and 
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supervising clinical psychologist. By the end of the process, all staff were much 
more involved and responsive, which helped.  
 
However, as my research was not meeting a clinical need and involved screening 
a population that were relatively well, the relevance of my work to the clinicians 
took some time for them to appreciate. Following completion of testing with their 
patients, members of the team were receptive to the suggestions I made about 
adapting their delivery of clinical information. For example, using visual prompts 
to aid understanding of their diabetes. However, when I followed up with them 
after testing of participants, the majority of clinicians did not believe the 
information would change their practice.  
 
Many of the participants (and their referring clinicians at a later date) told me 
following completion of the measures how enjoyable they had found the tests. In 
addition, a lot of the participants were concerned about diabetes affecting the 
brain and how it could impact them. As such, some of my discussions with people 
were informal conversations about the problems associated with diabetes in older 
adults and what was understood in the literature about the condition in younger 
populations. No one in the sample had heard that diabetes was linked to 
cognitive changes in the brain in later life and this surprised me, as I would have 
thought this would have been discussed with people at risk. However, currently, 
the recommendations for cognitive screening are at a research not a clinical level 
(Sinclair et al., 2000; Cukierman et al., 2005). Diabetes UK, which is a source of 
information and advocacy for many people with diabetes, is yet to recommend 
that people be screened as part of their standardised diabetes care. Yet, in order 
to avoid disrupting the standardised diabetes care of patients in the clinic, I was 
steered away from recruiting the more complicated patients. Had there been any 
cognitive problems with these patients, arguably they would have benefited most 
from being tested.  
 
Until patient and clinicians are aware of the possible cognitive changes that can 
happen as a result of diabetes - both related to and independent of cognitive 
aging - it will be challenging to galvanise more support and interest outside of 
research circles.  
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4.6.1.1 Practical applications of the research 
Whilst this research has been exploratory in scope, it has been worthwhile for 
several reasons: firstly, to generate interest in an area of diabetes that has 
gained less interest outside of psychology and medicine; secondly, because of 
this reduced interest, becoming aware of potential difficulty in recruiting 
participants with diabetes for cognitive testing on a smaller scale. And finally, to 
generate some data that may indicate that, for some people with T2DM, there is 
no inevitability they will show cognitive impairment.  
 
From the literature gathered and concluding themes drawn, the audiences that 
may benefit from this information are people with diabetes, clinicians working in 
diabetes – including nurses, podiatrists and dieticians – and researchers. This is 
because cognitive impairment in diabetes is a relatively unknown area compared 
to other areas of concern for the condition, and younger people with T2DM being 
impacted by cognition is even less known. 
 
From the observed sample, it was found that executive functioning was better in 
this group, which was unexpected. In reflection of the performance of the 
sampled participants, I will outline both a possible biological and psychological 
formulation of this result: The biological reason for this could be that on the 
whole, the participants’ diabetes was ‘well-controlled’’, to the extent that it did not 
affect their performance on the cognitive tests of executive function. It has been 
mentioned that the participants were selected through a triage of a clinician in the 
clinic. As such, those who were not managing their diabetes to a good enough 
standard were unlikely to be selected. Therefore, those who came to testing were 
unlikely to have issues with their diabetes care, and theoretically did not have 
issues with their executive function. 
 
A possible psychological explanation of the unexpected result in executive 
function is that the people that chose to come to testing were self-selecting in two 
ways: firstly, in that they were able to attend and balance this with the demands 
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on their time e.g. job or parenting. This would indicate a real life example of 
adequate executive function. Secondly, they knew they were able to perform well 
on tests of this nature e.g. doing tasks requiring concentration and an ability to 
hold things in mind.  
 
This explanation is not applicable to all participants. At the group level, executive 
function was a relative strength but individually some people did have poorer 
performance on some subtests of executive function. However, it is important to 
consider possible explanations for the unexpected result, which was found from 
testing. This could provide some useful data to provide to clinicians, namely that 
those that are managing their condition ‘well’, may be doing so because they 
have superior skills in executive function relative to other people with the 
condition. Therefore, it could be useful to consider measures that support 
improved executive function for those in clinic who are not managing their 
condition ‘well’, rather than treatment as usual. An example of this could be 
providing more support e.g. pill boxes that remind you to take medication, 
improved ways of asking clinicians questions e.g. a dedicated email address or 
developing an application with better diabetes-related information contained 
within it. Theoretically, interventions such as these could have implications for 
improved management and diabetic control for other patients’ that are struggling 
with their regimen.  
 
To date, I am unaware of a study has been done using the parameters chosen in 
this research. There are studies which assessed premorbid functioning/optimal 
ability, those that looked at younger adults e.g. around age 50, but none that 
combined those factors together and recruited primarily for a younger sample. 
Although the results from the analysis were not always in the direction expected, 
this is most likely attributable to the small sample size. Therefore, there is the 
possibility of finding a relationship with a larger sample and a suitable control 
group.  
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It will take some time to better understand the pathogenesis and impact of the 
condition becoming more common in younger adults and unfortunately, the most 
helpful part of diabetes care is prevention rather than working within the limits of 
what we know (Kumar & Singh, 2010). In the meantime, there have been calls to 
add cognitive dysfunction to the list of complications from chronic diabetes for 
over ten years (Sinclair et al., 2000; Cukierman et al., 2005), which I also support. 
These shifts in thinking can also help support clinicians on the frontline, 
especially with the additional knowledge of why cognition is so pivotal in diabetes.  
 
4.7 Conclusion 
 
This study explored premorbid functioning in younger adults with T2DM, and 
considered the participants’ performance on a series of cognitive tests, for any 
associated patterns of cognitive functioning and/or diabetes-related health 
indicators.  
 
In this particular sample, estimates of premorbid functioning were not useful for 
predicting performance on a set of tests that measure different cognitive function.  
Some relationships were found between health indicators connected to diabetes 
and cognition in the direction expected, including cholesterol and attention, 
executive function, visuo-spatial construction and learning and memory, and 
Hba1c and learning and memory and verbal-spatial construction.  
 
The sample was also assessed for cognitive impairment using scores of optimal 
ability as a baseline measurement: there was no significant decrease between 
scores of optimal ability and cognitive tests. But, there was an improvement 
between a test of executive function and optimal ability, which based on previous 
literature, is considered anomalous.  
 
As diabetes is a syndrome, its pathogenesis is multifactorial, which may be why 
cognitive impairment is not always present in people across the life span that 
have the condition. However, further research will be needed on a larger scale to 
establish the presence of cognitive impairment in younger adults with diabetes.  
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6. APPENDICES 
 
6.1 Appendix A: Participant Information Sheets for the Camden Research 
Site 
 
Participant Information Sheet:  v1.2 (1st September 2016) 203389 
UNIVERSITY OF EAST LONDON 
School of Psychology 
Stratford Campus 
Water Lane 
London E15 4LZ 
 
PARTICIPANT INFORMATION SHEET 
 
Project Title:  Cognitive function & Type 2 Diabetes: A Study Using Working Age Adults 
 
Principal Investigator(s):  Katy Lucas 
    E-mail: u1438310@uel.ac.uk 
    Telephone: 0208 223 4174 
 
Invitation to Participate in a Research Study 
The purpose of this letter is to provide you with the information that you need to consider 
in deciding whether to participate a research study. The study is being conducted as part 
of my Doctoral degree in Clinical Psychology at the University of East London. 
 
I would like to invite you to take part in a research study.  Before you decide whether to 
take part you need to understand why the research is being done and what it will involve.  
Please read through the following information carefully before deciding whether or not 
you would like to take part in the research.  Talk to others about the study if you wish.  If 
something needs clarification or you have any unanswered questions please do not 
hesitate to ask the researcher/research supervisor. The study is part of a Doctoral 
Degree in Clinical Psychology.   
 
What is the purpose of the study? 
The aim of the study is to try to understand how Type 2 Diabetes may affect people’s 
ability to do certain tasks. This will help us understand if the condition in younger adults 
should be understood differently to other people with diabetes. 
 
By understanding how this population may vary in their ability, services will consider 
making changes in order to improve people’s treatment. Consequently, future practice 
may be altered to better meet the needs of younger adults with Type 2 Diabetes. 
 
Why have I been invited? 
You have been invited to take part in this study, as you have Type 2 Diabetes. I am 
interested in finding out how this condition might affect your performance on certain 
tests. 
 
What will I be asked to do if I agree to take part? 
The researcher will invite you for a meeting lasting between 90-120minutes. You will be 
asked to do some puzzles and answer some questions. The questions will be decided 
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before hand but will assess you on different skills you use everyday. It is not a meeting 
you would need to prepare for or need to know specific information. 
 
Are there any disadvantages or risks to taking part? 
Meeting with the researcher might make you more aware of your ability in certain areas. 
You may find certain tasks easier than others. However, if you feel any discomfort or 
distress, upon finishing the meeting you will be given the opportunity to talk to the 
researcher about them. Additionally, I would be happy to contact someone at the hospital 
or clinic for you to talk to or provide contact details of other organisations that can offer 
you support. 
 
What will happen to the results of the research study? 
The results of the study will be written up as a doctoral thesis and submitted for 
publication in a journal.  In all written material of this study your identity will remain 
anonymous.  The data will be stored for three years, following which time it will be 
shredded and disposed of. 
 
Will the information I give be accessible to the clinicians/team in XXX Trust? 
Only the researcher and her research supervisor will have access to the information you 
provide.  Your clinicians will not be notified about your participation or the information 
that you have provided. Furthermore, your participation in this study will not affect your 
treatment. We can provide some information on your performance that could be useful 
for you about your cognitive strengths and abilities you could be supported with. 
However, if you feel any discomfort or distress, I would encourage you to seek support 
from either a clinician in the service or any of the organisations attached. 
 
Will the information I provide remain confidential? 
All the information provided by you is completely confidential; all paper information will 
be kept in a locked filing cabinet.  Your personal information will be kept separate from 
the tasks you complete, which will be given a code with no identifying personal 
information attached to them. Your real name will not be used in the analysis or write up 
of the study. The answer sheets will be saved onto a computer system, which will only 
be accessible by the researcher and her supervisor through a password protected 
system. 
 
Location:  where will the meetings take place? 
Meetings will take place at the clinic or hospital where you have your diabetes care or at 
the University of East London (Stratford campus) depending on your preference. 
 
Do I have to take part? 
No.  It is entirely up to you.  You are not obliged to take part in this study and you are 
free to withdraw at any time. Should you choose to withdraw from the study, you may do 
so without disadvantage to yourself and without giving any reason. This would not affect 
your usual care at the Camden Diabetes Service. 
 
After May 8th 2017, all data will be anonymised and I will not be able to identify your data 
so removal of your data will not be possible. All data will be destroyed two years 
following completion of the research (completion date: May 2017) or following publication 
of the data, whichever date is earlier. 
 
 
  111 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, well-being and dignity.  In 
addition, ethics approval has been obtained from the University of East London. 
 
Please feel free to ask me any questions. If you are happy to continue you will be asked 
to sign a consent form prior to your participation. Please retain this invitation letter for 
reference. 
 
What if I have any complaints? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researcher who will do their best to answer your questions (contact number: 020 8223 
4174).  If you remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure or the UEL Ethics Committee.  Details can be obtained from 
the researcher/research supervisor below. 
 
If you have any questions or concerns about how the study has been conducted, please 
contact the study’s supervisor:  
 
Matthew Jones Chester, School of Psychology, University of East London, Water Lane, 
London E15 4LZ.(Tel: 020 8223 4174. E-mail: m.h.jones-chesters@uel.ac.uk) 
or  
Chair of the School of Psychology Research Ethics Sub-committee: Dr. Mark Finn, 
School of Psychology, University of East London, Water Lane, London E15 4LZ. 
(Tel: 020 8223 4493. Email: m.finn@uel.ac.uk) 
or 
The Patient Advice and Liaison Service at the Royal Free Hospital 
 
The patient advice and liaison service for the Royal Free Hospital in the hospital’s main 
reception.  
The service is open from 10am to 4pm, Monday to Friday, except Wednesday, when the 
service is open from 10.30am to 4pm.  
You can contact the team using the following details:  
Tel: 020 7472 6446/6447; (020 7472 6445 - 24 hour answer phone) 
Fax: 020 7472 6463 
SMS: 447860023323 (Deaf, hard of hearing and hearing impaired patients only) 
Email: rf.pals@nhs.net 
Thank you in anticipation. 
 
Yours sincerely, 
 
 
Katy Lucas 
November 2016 
 
 
Thank you for taking the time to read this information sheet. Please keep for future 
reference. 
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6.2 Appendix B: NHS Research Ethics Committee Provisional Approval 
 
 
 
 
 
 
West Midlands - Black Country Research Ethics 
Committee  
The Old Chapel  
Royal Standard Place 
Nottingham 
NG1 6FS 
23 August 2016 
 
Ms Katy Lucas  
Trainee Clinical Psychologist 
Royal Free Hospital NHS Foundation Trust 
University of East London: School of Psychology  
Water Lane 
LONDON  
E15 4LZ 
 
 
Dear Ms Lucas 
 
Study title: Cognitive Function in Type 2 Diabetes: A Study Using 
 Younger Adults 
REC reference: 16/WM/0387 
IRAS project ID: 203389 
 
The Proportionate Review Sub-Committee of the West Midlands - Black Country 
Research Ethics Committee reviewed the above application on 22 August 2016. 
 
Provisional opinion 
 
The Sub-Committee would be content to give a favourable ethical opinion of the 
research, subject to clarification of the following issues and/or the following 
changes being made to the documentation for study participants: 
 
1. The methodology of the study must be clarified at section A13 of 
the application. A clear outline is requested to detail what the 
study plans to do, and how this will be achieved.  
2. The study title must be corrected across the application and all study 
documentation to read; “Cognitive Function in Type 2 Diabetes: A 
Study Using  
Working Age Adults”. 
3. The Participant Information Sheet must be updated as follows;  
a. To contain the details of the local PAL Service. 
b. To amend the contradictory information given within the section 
titled;  
‘Do I have to take part?’. 
4. The Consent Form must be revised to; 
a. Condense the points and reduce the number of consent boxes.  
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b. Contain the name of the researcher.  
5. A Protocol for what would happen in the event of incidental 
findings arising from the Beck Depression Inventory is requested.  
6. The study exclusion criteria must be updated to include 
persons who are colour blind.  
7. The reference to the sexual health clinic on page nine of the IRAS 
application should be explained or corrected as appropriate. 
8. It is asked if the historical controls are valid for the ethnic 
groups likely participate.  
9. Please clarify the expected time expense required of the assessments. 
 
 
When submitting a response to the Sub-Committee, the requested information should 
be electronically submitted from IRAS. A step-by-step guide on submitting your 
response to the REC provisional opinion is available on the HRA website using the 
following link: http://www.hra.nhs.uk/nhs-research-ethics-committee-rec-submitting-
response-provisional-opinion/ 
 
Please submit revised documentation where appropriate underlining or otherwise 
highlighting the changes which have been made and giving revised version numbers 
and dates. You do not have to make any changes to the REC application form unless 
you have been specifically requested to do so by the REC. 
 
Authority to consider your response and to confirm the final opinion on behalf of 
the Committee has been delegated to the Chair. 
 
Please contact the REC office if you need any further clarification or would find it 
helpful to discuss the changes required with the lead reviewer. 
 
The Committee will confirm the final ethical opinion within 7 days of receiving a 
full response. A response should be submitted by no later than 22 September 
2016. 
 
Summary of discussion at the meeting 
 
Social or scientific value; scientific design and conduct of the study 
 
The Sub-Committee considered the proposal difficult to follow and the methodology 
unclear. A clear outline was requested at section A13 of the application to detail what the 
study plans to do, and how this will be achieved. 
 
The Sub-Committee presumed the reference to the sexual health clinic on page nine of 
the application was included in error, and requested this reference be explained or 
corrected. 
 
The Sub-Committee noted the incorrect study title was used within the IRAS application 
and across study documentation, and requested that this be corrected throughout to 
read; “Cognitive Function in Type 2 Diabetes: A Study Using Working Age Adults”. 
 
The Sub-Committee discussed the colour test to be conducted as part of the cognitive 
assessments and commented that this is not appropriate for participants who are colour 
blind, adding that the use of such persons would give false results. The Sub-Committee 
agreed that the study exclusion criteria should be updated to include this group. 
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The Sub-Committee commented on the number of assessments required of the 
participants, and questioned if the proposed 90 minutes is realistic. The Sub-
Committee added that the time varies across the application from 90-120 minutes 
and requested the expected time expense be clarified. 
 
The Sub-Committee considered the established norms of the tests and the ethnic 
diversity in Camden. The Sub-Committee stated that norms do need ethnic origin 
correction, and noted that this is not considered in the application. The Sub-Committee 
asked if the historical controls are valid for the ethnic groups likely to participate. 
 
Care and protection of research participants; respect for potential and 
enrolled participants’ welfare and dignity 
 
The Sub-Committee queried what would happen in the event of incidental findings 
arising from the Beck Depression Inventory scale, and requested that a protocol for 
this be submitted. 
 
Informed consent process and the adequacy and completeness 
of participant information 
 
The Sub-Committee discussed the Participant Information Sheet and 
noted the two paragraphs under the section “Do I have to take part” 
are contradictory and must be revised. 
 
The Sub-Committee noted that the document is without reference to the local 
PAL Service, and requested details of this be added. 
 
The Sub-Committee reviewed the Consent Form and asked for the name of 
the researcher to be added to the document. The Sub-Committee considered 
there to be too many boxes on the Consent Form, and agreed that the points 
should be condensed. 
 
Documents reviewed 
 
The documents reviewed were: 
 
Document Version Date 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 
only) [Academic Indemnity Insurance] 
Version 1 01 August 2015 
Interview schedules or topic guides for participants [Protocol] 1.1 04 August 2016 
Interview schedules or topic guides for participants [Protocol] 1.1 14 August 2016 
IRAS Application Form [IRAS_Form_12082016]  12 August 2016 
IRAS Checklist XML [Checklist_15082016]  15 August 2016 
Letter from sponsor [Confirmed Registration] Version 1 27 June 2016 
Other [Debrief Sheet] 1.1 05 August 2016 
Other [Research Proposal - Initial Academic Feedback] 1 05 August 2016 
Other [DKEFS - Colour Word Inference] 1 15 August 2016 
Other [DKEFS - Trail Making] 1 15 August 2016 
Other [DKEFS - Verbal Fluency] 1 15 August 2016 
Other [Test of Premorbid Functioning] 1 15 August 2016 
Other [WAIS - Coding] 1 15 August 2016 
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Other [WAIS - Block Design] 1 15 August 2016 
Other [WAIS - Digit Span] 1 15 August 2016 
Other [WAIS - Similarities] 1 15 August 2016 
Other [WMS - Visual Reproduction and Logical Memory] 1 15 August 2016 
Other [Becks Anxiety Inventory] 1 15 August 2016 
Other [Becks Depression Inventory] 1 15 August 2016 
Participant consent form [Participant Consent Form] 1.1 14 August 2016 
Participant information sheet (PIS) [Participant Information Sheet] 1.1 05 August 2016 
Referee's report or other scientific critique report [Email and Letter 
Confirming Academic Approval of the Study] 
1.0 05 August 2016 
Research protocol or project proposal [Amended Research 
Proposal] 
Version 1 05 August 2016 
Sample diary card/patient card [Record Form] 1.1 05 August 2016 
Summary CV for Chief Investigator (CI) [CV] Version 1 13 June 2016 
Summary CV for supervisor (student research) [Summary CV for 
supervisor] 
1.0 05 August 2016 
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Membership of the Committee 
 
The members of the Committee who were present at the meeting 
are listed on the attached sheet. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees and complies fully 
with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
16/WM/0387                          Please quote this number on all 
correspondence 
 
Yours sincerely 
PP  
 
Reverend Keith Lackenby 
Acting Chair 
 
Email: nrescommittee.westmidlands-blackcountry@nhs.net 
 
Enclosures:                  List of names and professions of 
members who took part in the review 
 
Copy to:                       Professor Neville Punchard 
Miranda Rosenthal, Royal Free Hospital NHS Foundation Trust 
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West Midlands - Black Country 
Research Ethics Committee 
 
Attendance at PRS Sub-Committee of the REC 
meeting on 22 August 2016 
 
 
 
Committee Members: 
 
Name Profession Present Notes 
Mrs Chris Bell Board Member Yes  
Reverend Keith Lackenby 
(Acting Chair) 
Reverend Yes  
Dr Tony Zalin Expert Member Yes  
Also in attendance: 
 
Name Position (or reason for attending) 
Miss Lindsey Wallace REC Assistant 
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6.3 Appendix C: Letter to Address Issues from REC Board 
 
Katy Lucas 
11 Springfield 
Avenue Road 
London 
SE25 4ED 
16th September 2016 
Reverend Keith Lackenby 
Acting Chair 
West Midlands – Black Country REC 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
Dear Reverend Lackenby, 
 
RE: Amendments to IRAS 203389 “Cognitive Function in Type 2 Diabetes: 
A Study Using Working Age Adults” 
 
Thank you for the guidance received on 23rd August 2016 in respect of the ethics 
form. Based on the feedback, I wanted to address each item in turn: 
 
1. The methodology of the study must be clarified at section A13 of the 
application. A clear outline is requested to detail what the study plans to 
do, and how this will be achieved. 
I have updated this section, including providing an outlined summary of what the 
study plans to do, and how this will be achieved. 
 
2. The study title must be corrected across the application and all study 
documentation to read; “Cognitive Function in Type 2 Diabetes: A Study 
Using Working Age Adults”. 
This has been updated to read: Cognitive Function & Type 2 Diabetes – A Study 
Using Working Age Adults.  
 
3. The Participant Information Sheet must be updated as follows; 
a. To contain the details of the local PAL Service. 
This has been updated. Please see the attached PIS. 
 
b. To amend the contradictory information given within the section titled; 
‘Do I have to take part?’ 
This has been updated on the Participant Information Sheet to clarify the 
difference between withdrawing participation from the study and when it is not 
possible for anonymised data to be removed. Please see the updated 
Participation Information Sheet.  
 
4. The Consent Form must be revised to; 
a. Condense the points and reduce the number of consent boxes. 
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The points have been condensed and the number of consent boxes reduced. 
Please see the updated Consent Form. 
 
b. Contain the name of the researcher. 
This has been updated. Please see the updated Consent Form. 
 
5. A Protocol for what would happen in the event of incidental findings 
arising from the Beck Depression Inventory is requested. 
This has been added into A13 and reads: 
 
The BDI score will be computed and, if above 25, items subscribed to will 
be reviewed items. For high scores participants will be advised in session that 
their scores is high and suggestive of mood problems. Participants will be 
provided with information on referring to their local psychology (IAPT) service, 
and to seek the advice of their GP for further help. If participants subscribe to 
item 9 (risk of harm to self) a risk assessment will be undertaken. The results will 
be discussed with the supervisor to determine the most appropriate action (e.g., 
to contact referring clinician, duty social worker or GP). If the RA suggests an 
immediate risk to self or others, advice will be given on attending to see their GP 
and/or A&E services.  
 
6. The study exclusion criteria must be updated to include persons who are 
colour blind. 
The exclusion criteria in the IRAS form has been updated.  
 
7. The reference to the sexual health clinic on page nine of the IRAS 
application should be explained or corrected as appropriate. 
This has been removed as it was submitted in error. 
 
8. It is asked if the historical controls are valid for the ethnic groups likely 
participate. 
The neuropsychological tests used are valid for primary speakers of English (first 
or second language English speakers who use English as their main 
language) except for the TOPF.  It is unfortunately the case that no 
neuropsychological test set exists for non-Western cultural groups that have the 
required sensitivity for this study.  The results in individual cases will be 
interpreted in context and with caution.  However, no person will be excluded 
from the study on the basis of their cultural and/or ethnic identity. 
 
 
9. Please clarify the expected time expense required of the assessments. 
This had been updated in all sections and documentation of the application to 
read 90-120 minutes. 
 
I hope there is sufficient information in the letter and the proposal to address the 
suggestions made. I look forward to hearing from you. 
 
Best wishes, 
 
Katy Lucas 
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6.4 Appendix D: NHS Research Favourable Opinion Letter 
 
 
 
 
 
West Midlands - Black Country Research Ethics 
Committee  
The Old Chapel 
Royal Standard Place 
Nottingham  
NG1 6FS 
 
 
 
 
 
23 September 2016 
 
Miss Katy Lucas 
School of Psychology, University of East London  
Stratford Campus 
Water Lane  
E15 4LZ 
 
Dear Miss Lucas 
 
Study title: Cognitive Function & Type 2 Diabetes: A Study of 
 Working Age Adults 
REC reference: 16/WM/0387 
IRAS project ID: 203389 
 
Thank you for your letter of 20/09/2016, responding to the 
Proportionate Review Sub-Committee’s request for changes to the 
documentation for the above study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
 
We plan to publish your research summary wording for the above study on the 
HRA website, together with your contact details. Publication will be no earlier than 
three months from the date of this favourable opinion letter. The expectation is 
that this information will be published for all studies that receive an ethical opinion 
but should you wish to provide a substitute contact point, wish to make a request 
to defer, or require further information, please contact the REC Manager Georgia 
Copeland, nrescommittee.westmidlands-blackcountry@nhs.net 
 
Please note: This is the favourable opinion of the REC only and does not 
allow you to start your study at NHS sites in England until you receive 
HRA Approval 
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Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the 
study. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
Management permission must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission should be sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements. Each NHS 
organisation must confirm through the signing of agreements and/or other documents 
that it has given permission for the research to proceed (except where explicitly 
specified otherwise). 
 
Guidance on applying for HRA Approval (England)/ NHS permission for research is 
available in the Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk. 
 
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites (“participant identification centre”), guidance 
should be sought from the R&D office on the information it requires to give 
permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of management permissions 
from host organisations. 
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant 
is recruited but no later than 6 weeks after recruitment of the first participant. 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as 
part of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is 
registered but for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials 
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will be registered, however, in exceptional circumstances non registration may be 
permissible with prior agreement from the HRA. Guidance on where to register is provided 
on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see 
“Conditions of the favourable opinion” above). 
 
Approved documents 
 
The documents reviewed and approved by the Committee are: 
Document Version 
 
Date  
Covering letter on headed paper [Letter to Address 
Amendment 1.1 
2
0 
September 
2016 
Requests from REC board]     
Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors Version 1 
0
1 August 2015 
only) [Academic Indemnity Insurance]     
Interview schedules or topic guides for participants 
[Protocol] 1.1 
1
4 August 2016 
    
IRAS Application Form [IRAS_Form_20092016]  
2
0 
September 
2016 
    
IRAS Application Form XML file [IRAS_Form_20092016]  
2
0 
September 
2016 
    
IRAS Checklist XML [Checklist_20092016]  
2
0 
September 
2016 
    
Letter from sponsor [Confirmed Registration] Version 1 
2
7 June 2016 
    
Other [Research Proposal - Initial Academic Feedback] 1 
0
5 August 2016 
    
Other [DKEFS - Colour Word Inference] 1 
1
5 August 2016 
    
Other [DKEFS - Trail Making] 1 
1
5 August 2016 
    
Other [DKEFS - Verbal Fluency] 1 
1
5 August 2016 
    
Other [Test of Premorbid Functioning] 1 
1
5 August 2016 
    
Other [WAIS - Coding] 1 
1
5 August 2016 
    
Other [WAIS - Block Design] 1 
1
5 August 2016 
    
Other [WAIS - Digit Span] 1 
1
5 August 2016 
    
Other [WAIS - Similarities] 1 
1
5 August 2016 
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Other [WMS - Visual Reproduction and Logical Memory] 1 
1
5 August 2016 
    
Other [Becks Anxiety Inventory] 1 
1
5 August 2016 
    
Other [Becks Depression Inventory] 1 
1
5 August 2016 
    
Other [Debrief Sheet] 1.2 
2
0 
September 
2016 
    
Participant consent form [Participant Consent Form] 1.3 
2
0 
September 
2016 
    
Participant information sheet (PIS) [Participant 
Information Sheet] 1.3 
2
0 
September 
2016 
    
Referee's report or other scientific critique report [Email 
and Letter 1.0 
0
5 August 2016 
Confirming Academic Approval of the Study]     
Research protocol or project proposal [Amended 
Research Version 1 
0
5 August 2016 
Proposal]     
Sample diary card/patient card [Record Form] 1.2 
2
0 
September 
2016 
    
Summary CV for Chief Investigator (CI) [CV] Version 1 
1
3 June 2016 
    
Summary CV for supervisor (student research) 
[Summary CV for 1.0 
0
5 August 2016 
supervisor]     
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
•  Notifying substantial 
amendments •  Adding new 
sites and investigators 
•  Notification of serious breaches of the 
protocol •  Progress and safety reports  
•  Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
Feedback 
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You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
16/WM/0387 Please quote this number on all correspondence 
 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
 
 
 
Reverend Keith Lackenby  
Chair 
 
Email: nrescommittee.westmidlands-blackcountry@nhs.net 
 
Enclosures: “After ethical review – guidance for researchers”  
Copy to: Professor Neville Punchard 
Dr Paul Chadwick, Royal Free London Hospital NHS Foundation Trust 
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6.5 Appendix E: HRA Approval Letter 
 
 
 
 
 
 
Miss Katy Lucas  
School of Psychology, University of East London Stratford Campus 
Water Lane E15 4LZ 
 Email:
 
hra.approval@nhs.net
 
21 October 2016 
 
Dear Miss Lucas,  
  Letter of HRA Approval  
    
Study title: Cognitive Function & Type 2 Diabetes: A Study of Working 
 Age Adults 
IRAS project ID: 203389  
REC reference: 16/WM/0387 
Sponsor University of East London 
 
 
I am pleased to confirm that HRA Approval has been given for the above referenced 
study, on the basis described in the application form, protocol, supporting 
documentation and any clarifications noted in this letter. 
 
 
Participation of NHS Organisations in England  
The sponsor should now provide a copy of this letter to all participating NHS 
organisations in England. 
 
 
Appendix B provides important information for sponsors and participating NHS 
organisations in England for arranging and confirming capacity and capability. Please 
read Appendix B carefully, in particular the following sections: 
 
1. Participating NHS organisations in England – this clarifies the types of 
participating organisations in the study and whether or not all organisations 
will be undertaking the same activities  
2. Confirmation of capacity and capability - this confirms whether or not each type 
of participating NHS organisation in England is expected to give formal 
confirmation of capacity and capability. Where formal confirmation is not 
expected, the section also provides details on the time limit given to participating 
organisations to opt out of the study, or request additional time, before their 
participation is assumed.  
3. Allocation of responsibilities and rights are agreed and documented (4.1 of 
HRA assessment criteria) - this provides detail on the form of agreement to be 
used in the study to confirm capacity and capability, where applicable.  
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Further information on funding, HR processes, and compliance with HRA criteria and 
standards is also provided. 
 
It is critical that you involve both the research management function (e.g. R&D office) 
supporting each organisation and the local research team (where there is one) in setting 
up your study. Contact details 
 
and further information about working with the research management function for 
each organisation can be accessed from www.hra.nhs.uk/hra-approval. 
 
 
Appendices  
The HRA Approval letter contains the following appendices:  
• A – List of documents reviewed during HRA assessment  
• B – Summary of HRA assessment 
 
After HRA Approval  
The document “After Ethical Review – guidance for sponsors and investigators”, issued 
with your REC favourable opinion, gives detailed guidance on reporting expectations 
for studies, including:  
• Registration of research  
• Notifying amendments  
• Notifying the end of the study  
The HRA website also provides guidance on these topics, and is updated in the 
light of changes in reporting expectations or procedures. 
 
 
In addition to the guidance in the above, please note the following:  
• HRA Approval applies for the duration of your REC favourable opinion, 
unless otherwise notified in writing by the HRA.  
· Substantial amendments should be submitted directly to the Research Ethics 
Committee, as detailed in the After Ethical Review document. Non-substantial 
amendments should be submitted for review by the HRA using the form 
provided on the HRA website, and emailed to hra.amendments@nhs.net.  
· The HRA will categorise amendments (substantial and non-substantial) and 
issue confirmation of continued HRA Approval. Further details can be found on 
the HRA website. 
 
 
Scope  
HRA Approval provides an approval for research involving patients or staff in NHS 
organisations in England. 
 
If your study involves NHS organisations in other countries in the UK, please 
contact the relevant national coordinating functions for support and advice. 
Further information can be found at http://www.hra.nhs.uk/resources/applying-for-
reviews/nhs-hsc-rd-review/. 
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If there are participating non-NHS organisations, local agreement should be obtained 
in accordance with the procedures of the local participating non-NHS organisation. 
 
 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service 
to all applicants and sponsors. You are invited to give your view of the service you 
have received and the application procedure. If you wish to make your views known 
please email the HRA at hra.approval@nhs.net.  
Additionally, one of our staff would be happy to call and discuss your experience of HRA 
Approval. 
 
HRA Training  
We are pleased to welcome researchers and research management staff at our 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
Your IRAS project ID is 203389. Please quote this on all correspondence. 
 
 
Yours sincerely 
 
 
Steph Blacklock  
Senior Assessor 
 
 
Email: hra.approval@nhs.net 
 
 
 
 
 
Copy to: Professor Michael Seed, University of East London, Sponsor Contact 
 Dr  Paul Chadwick, Royal Free London Hospital NHS Foundation Trust, Lead 
 R&D Contact 
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Appendix A - List of Documents 
 
 
The final document set assessed and approved by HRA Approval is listed below. 
 
 
Document Version Date 
Covering letter on headed paper [Letter to Address 
Amendment 1.1 
2
0 
September 
2016 
Requests from REC board]    
Evidence of Sponsor insurance or indemnity (non NHS 
Sponsors Version 1 
0
1 August 2015 
only) [Academic Indemnity Insurance]    
Interview schedules or topic guides for participants 
[Protocol] 1.1 
1
4 August 2016 
    
IRAS Application Form [IRAS_Form_20092016]  
2
0 
September 
2016 
    
IRAS Application Form XML file [IRAS_Form_20092016]  
2
0 
September 
2016 
    
Letter from sponsor [Confirmed Registration] Version 1 
2
7 June 2016 
    
Other [Debrief Sheet] 1.1 
0
5 August 2016 
    
Other [DKEFS - Colour Word Inference] 1 
1
5 August 2016 
    
Other [DKEFS - Trail Making] 1 
1
5 August 2016 
    
Other [DKEFS - Verbal Fluency] 1 
1
5 August 2016 
    
Other [Test of Premorbid Functioning] 1 
1
5 August 2016 
    
Other [WAIS - Coding] 1 
1
5 August 2016 
    
Other [WAIS - Block Design] 1 
1
5 August 2016 
    
Other [WAIS - Digit Span] 1 
1
5 August 2016 
    
Other [WAIS - Similarities] 1 
1
5 August 2016 
    
Other [WMS - Visual Reproduction and Logical Memory] 1 
1
5 August 2016 
    
Other [Becks Anxiety Inventory] 1 
1
5 August 2016 
    
Other [Becks Depression Inventory] 1 
1
5 August 2016 
    
Other [Debrief Sheet] 1.2 
2
0 
September 
2016 
    
Participant consent form [Participant Consent Form] 1.3 
2
0 
September 
2016 
    
Participant information sheet (PIS) [Participant 
Information Sheet] 1.3 
2
0 
September 
2016 
    
Referee's report or other scientific critique report [Email 1.0 0 August 2016 
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and Letter 5 
Confirming Academic Approval of the Study]    
Sample diary card/patient card [Record Form] 1.2 
2
0 
September 
2016 
    
Summary CV for Chief Investigator (CI) [CV] Version 1 
1
3 June 2016 
    
Statement of Activities 1.0 
2
1 October 2016 
    
Schedule of Events 1.0 
2
1 October 2016 
    
 
Appendix B - Summary of HRA Assessment 
 
 
This appendix provides assurance to you, the sponsor and the NHS in England that 
the study, as reviewed for HRA Approval, is compliant with relevant standards. It 
also provides information and clarification, where appropriate, to participating NHS 
organisations in England to assist in assessing and arranging capacity and 
capability. 
 
For information on how the sponsor should be working with participating NHS 
organisations in England, please refer to the, participating NHS organisations, 
capacity and capability and Allocation of responsibilities and rights are agreed 
and documented (4.1 of HRA assessment criteria) sections in this appendix. 
 
The following person is the sponsor contact for the purpose of addressing 
participating organisation questions relating to the study: 
 
Miss Katy Lucas u1438310@uel.ac.uk 
 
HRA assessment criteria 
Section HRA Assessment Criteria Compliant with Comments 
  Standards  
    
1.1 IRAS application completed Yes No comments 
 correctly   
    
    
2.1 Participant information/consent Yes No comments 
 documents and consent   
 process   
    
    
3.1 Protocol assessment Yes No comments 
    
    
4.1 Allocation of responsibilities Yes Statement of Activities and Schedule of 
 and rights are agreed and  Events provided for use with the 
 documented  participating organisation. 
    
  130 
 
 
4.2 Insurance/indemnity Yes Applicant has confirmed that a valid 
 arrangements assessed  insurance certificate will be in place 
   prior to study start. 
   Where applicable, independent 
   contractors (e.g. General Practitioners) 
   should ensure that the professional 
   indemnity provided by their medical 
   defence organisation covers the 
   activities expected of them for this 
    
Section HRA Assessment Criteria Compliant with  Comments 
  Standards    
     
   research study  
    
4.3 Financial arrangements Yes There is no external funding acquired 
 assessed  for this study and therefore no funds 
   distributed to participating 
   organisations.  
     
      
5.1 Compliance with the Data Yes No comments  
 Protection Act and data     
 security issues assessed     
     
5.2 CTIMPS – Arrangements for Not Applicable Not Applicable  
 compliance with the Clinical     
 Trials Regulations assessed     
     
5.3 Compliance with any Not Applicable Not Applicable  
 applicable laws or regulations     
     
      
6.1 NHS Research Ethics Yes No comments  
 Committee favourable opinion     
 received for applicable studies     
     
6.2 CTIMPS – Clinical Trials Not Applicable Not Applicable  
 Authorisation (CTA) letter     
 received     
     
6.3 Devices – MHRA notice of no Not Applicable Not Applicable  
 objection received     
     
6.4 Other regulatory approvals Not Applicable Not Applicable  
 and authorisations received     
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Participating NHS Organisations in England 
 
This provides detail on the types of participating NHS organisations in the 
study and a statement as to whether the activities at all organisations are the 
same or different.  
This is a single site, student, qualitative study with one participating organisation and 
therefore one site type. The study aim is to begin a preliminary exploration of 
cognitive function in people with T2DM aged 18-55Y. Interested participants will 
undergo an interview, standardised tests and receive a profile of their cognitive 
strengths and areas for development. 
 
 
 
 
Confirmation of Capacity and Capability 
 
This describes whether formal confirmation of capacity and capability is 
expected from participating NHS organisations in England. 
 
Participating NHS organisations in England that are identifying participants and 
conducting interviews will be expected to formally confirm their capacity and capability 
to host this research.  
• Following issue of this letter, participating NHS organisations in England may 
now confirm to the sponsor their capacity and capability to host this research, 
when ready to do so. How capacity and capacity will be confirmed is detailed in 
the Allocation of responsibilities and rights are agreed and documented (4.1 of 
HRA assessment criteria) section of this appendix.  
· The Assessing, Arranging, and Confirming document on the HRA website 
provides further information for the sponsor and NHS organisations on 
assessing, arranging and confirming capacity and capability. 
 
 
 
Principal Investigator Suitability 
 
This confirms whether the sponsor position on whether a PI, LC or neither 
should be in place is correct for each type of participating NHS organisation in 
England and the minimum expectations for education, training and experience 
that PIs should meet (where applicable).  
Student researcher is acting as the local collaborator for the participating 
organisation. GCP training is not a generic training expectation, in line with 
the HRA statement on training expectations. 
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HR Good Practice Resource Pack Expectations 
 
This confirms the HR Good Practice Resource Pack expectations for the study 
and the pre-engagement checks that should and should not be undertaken 
 
Student researcher will require a letter of access if no other honorary accesses are 
already in place with the participating organisation. 
 
 
Other Information to Aid Study Set-up 
 
This details any other information that may be helpful to sponsors and 
participating NHS organisations in England to aid study set-up. 
 
• The applicant has indicated that they do not intend to apply for inclusion on 
the NIHR CRN Portfolio. 
 
  133 
6.6 Appendix F: Letter of Access from the Royal Free Hospital 
 
  
 
 
 
 
 
24/10/2016  
Dear Katy Janet Lucas  
Project ID: 9901 (Please quote in all correspondence) 
REC Ref: 16/WM/0387  
UKCRN ID:  
IRAS ID: 203389 
Title: Cognitive Function & Type 2 Diabetes: A Study of Working Age Adults 
   
Letter of access for research  
 
This letter should be presented to each participating organisation before you 
commence your research at that site. The participating organisation is Royal Free 
London NHS Foundation Trust.  
 
In accepting this letter, each participating organisation confirms your right of 
access to conduct research through their organisation for the purpose and on the 
terms and conditions set out below. This right of access commences on 
24/10/2016 and ends on 10/05/2017unless terminated earlier in accordance with 
the clauses below.  
 
You have a right of access to conduct such research as confirmed in writing in 
the letter of permission for research from the Royal Free London NHS 
Foundation Trust. Please note that you cannot start the research until the 
Principal Investigator for the research project has received a letter from us giving 
confirmation from the individual organisation(s) of their agreement to conduct the 
research.  
 
The information supplied about your role in research at the organisation(s) has 
been reviewed and you do not require an honorary research contract with the 
organisation(s). We are satisfied that such pre- engagement checks as we 
consider necessary have been carried out. Evidence of checks should be 
available on request to the organisation(s).  
 
You are considered to be a legal visitor to the organisations premises. You are 
not entitled to any form of payment or access to other benefits provided by the 
organisation(s) or this organisation to employees and this letter does not give rise 
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to any other relationship between you and the organisation(s), in particular that of 
an employee.  
 
While undertaking research through the organisation(s) you will remain 
accountable to your substantive employer but you are required to follow the 
reasonable instructions of the organisation(s) or those instructions given on their 
behalf in relation to the terms of this right of access.  
 
Where any third party claim is made, whether or not legal proceedings are 
issued, arising out of or in connection with your right of access, you are required 
to co-operate fully with any investigation by the organisation(s) in connection with 
any such claim and to give all such assistance as may reasonably be required 
regarding the conduct of any legal proceedings.  
 
You must act in accordance with the organisations policies and procedures, 
which are available to you upon request, and the Research Governance 
Framework.  
 
You are required to co-operate with the organisation(s) in discharging its/their 
duties under the Health and Safety at Work etc Act 1974 and other health and 
safety legislation and to take reasonable care for the health and safety of yourself 
and others while on the organisations premises. You must observe the same 
standards of care and propriety in dealing with patients, staff, visitors, equipment 
and premises as is expected of any other contract holder and you must act 
appropriately, responsibly and professionally at all times.  
 
If you have a physical or mental health condition or disability which may affect 
your research role and which might require special adjustments to your role, if 
you have not already done so, you must notify your employer and each 
organisation prior to commencing your research role at that organisation.  
 
You are required to ensure that all information regarding patients or staff remains 
secure and strictly confidential at all times. You must ensure that you understand 
and comply with the requirements of the NHS Confidentiality Code of Practice 
and the Data Protection Act 1998. Furthermore you should be aware that under 
the Act, unauthorised disclosure of information is an offence and such 
disclosures may lead to prosecution.  
 
You should ensure that, where you are issued with an identity or security card, a 
bleep number, email or library account, keys or protective clothing, these are 
returned upon termination of this arrangement. Please also ensure that while on 
the organisations premises you wear your ID badge at all times, or are able to 
prove your identity if challenged. Please note that the organisation(s) do not 
accept responsibility for damage to or loss of personal property.  
 
This organisation may revoke this letter and any organisation(s) may terminate 
your right to attend at any time either by giving seven days’ written notice to you 
or immediately without any notice if you are in breach of any of the terms or 
conditions described in this letter or if you commit any act that we reasonably 
consider to amount to serious misconduct or to be disruptive and/or prejudicial to 
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the interests and/or business of the organisation(s) or if you are convicted of any 
criminal offence. You must not undertake regulated activity if you are barred from 
such work. If you are barred from working with adults or children this letter of 
access is immediately terminated. Your employer will immediately withdraw you 
from undertaking this or any other regulated activity and you MUST stop 
undertaking any regulated activity immediately.  
Your substantive employer is responsible for your conduct during this research 
project and may in the circumstances described above instigate disciplinary 
action against you.  
 
No organisation will indemnify you against any liability incurred as a result of any 
breach of confidentiality or breach of the Data Protection Act 1998. Any breach of 
the Data Protection Act 1998 may result in legal action against you and/or your 
substantive employer.  
 
If your current role or involvement in research changes, or any of the information 
provided in your Research Passport changes, you must inform your employer 
through their normal procedures. You must also inform your nominated manager 
in the Royal Free London NHS Foundation Trust and the the Royal Free London 
NHS Foundation Trust R&D office.  
 
Yours sincerely  
  
 
  
Neil Hubbard  
Research Portfolio Manager  
Royal Free London NHS Foundation Trust  
 
cc: HR department of the substantive employer  
PI  
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6.7 Appendix G: UEL Ethical Approval 
 
School of Psychology Research Ethics Committee 
 
NOTICE OF ETHICS REVIEW DECISION  
 
For research involving human participants 
BSc/MSc/MA/Professional Doctorates in Clinical, Counselling and Educational 
Psychology 
 
 
REVIEWER: Rachel Tribe 
 
SUPERVISOR:  Matthew Jones Chesters 
 
COURSE: Professional Doctorate in Clinical Psychology 
 
STUDENT: Katy Lucas 
 
TITLE OF PROPOSED STUDY: Cognitive Function in Type 2 Diabetes Mellitus: A study using 
younger adults 
 
DECISION OPTIONS:  
 
1. APPROVED: Ethics approval for the above named research study has 
been granted from the date of approval (see end of this notice) to the date 
it is submitted for assessment/examination. 
 
2. APPROVED, BUT MINOR AMENDMENTS ARE REQUIRED BEFORE 
THE RESEARCH COMMENCES (see Minor Amendments box below): In 
this circumstance, re-submission of an ethics application is not required 
but the student must confirm with their supervisor that all minor 
amendments have been made before the research commences. Students 
are to do this by filling in the confirmation box below when all amendments 
have been attended to and emailing a copy of this decision notice to 
her/his supervisor for their records. The supervisor will then forward the 
student’s confirmation to the School for its records.  
 
3. NOT APPROVED, MAJOR AMENDMENTS AND RE-SUBMISSION 
REQUIRED (see Major Amendments box below): In this circumstance, a 
revised ethics application must be submitted and approved before any 
research takes place. The revised application will be reviewed by the 
same reviewer. If in doubt, students should ask their supervisor for support 
in revising their ethics application.  
 
DECISION ON THE ABOVE-NAMED PROPOSED RESEARCH STUDY 
(Please indicate the decision according to one of the 3 options above) 
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Approved 
 
 
Minor amendments required (for reviewer): 
 
 
This sounds like an interesting and important study.  I would ask that the trainee and 
supervisor have checked that NHS ethics is not needed for this study, as it doesn’t 
appear to be mentioned, unless I missed it? As the supervisor is an experienced clinician 
and researcher  I guess this this has been done, but it be  good for clarification to be 
given.  If this is done and the appropriate procedure followed I am happy with this study.  
I couldn’t find the age range for the study, but younger adults means over 18, so the 
participants would not be classified as  vulnerable  people. 
 
 
 
 
 
 
Major amendments required (for reviewer): 
 
 
 
 
 
 
 
 
 
 
 
        
ASSESSMENT OF RISK TO RESEACHER (for reviewer) 
 
If the proposed research could expose the researcher to any of kind of emotional, 
physical or health and safety hazard? Please rate the degree of risk: 
 
 
HIGH 
 
MEDIUM 
 
LOW 
 
 
Reviewer comments in relation to researcher risk (if any): 
 
 
 
 
Reviewer (Typed name to act as signature):    Prof R Tribe 
 
 
 
X 
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Date:  1.7.16 
 
This reviewer has assessed the ethics application for the named research study 
on behalf of the School of Psychology Research Ethics Committee 
 
 
Confirmation of making the above minor amendments (for students): 
 
I have noted and made all the required minor amendments, as stated above, before 
starting my research and collecting data. 
 
Student’s name (Typed name to act as signature):  
Student number:    
 
Date:  
 
(Please submit a copy of this decision letter to your supervisor with this box completed, if 
minor amendments to your ethics application are required) 
 
PLEASE NOTE:  
 
*For the researcher and participants involved in the above named study to be 
covered by UEL’s insurance and indemnity policy, prior ethics approval from the 
School of Psychology (acting on behalf of the UEL Research Ethics Committee), 
and confirmation from students where minor amendments were required, must be 
obtained before any research takes place.  
 
*For the researcher and participants involved in the above named study to be 
covered by UEL’s insurance and indemnity policy, travel approval from UEL (not 
the School of Psychology) must be gained if a researcher intends to travel 
overseas to collect data, even if this involves the researcher travelling to his/her 
home country to conduct the research. Application details can be found here: 
http://www.uel.ac.uk/gradschool/ethics/fieldwork/ 
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6.8 Appendix H: UREC Sponsorship Confirmation Letter 
 
 
 
 
 
 
 
7th November 2016 
 
Dear Katy, 
 
Project Title: Cognitive Function & Type 2 Diabetes: A Study of Working 
 Age Adults 
Researcher(s): Katy Lucas 
  
Principal Katy Lucas 
Investigator:  
  
 
I am writing to confirm that the application for the aforementioned NHS 
research study reference 16/WM/0387 has received UREC ethical approval 
and is sponsored by the University of East London. 
 
The lapse date for ethical approval for this study is 7th November 2020. If 
you require UREC approval beyond this date you must submit satisfactory 
evidence from the NHS confirming that your study has current NHS R&D 
ethical approval and provide a reason why UREC approval should be 
extended. 
 
Please note as a condition of your sponsorship by the University of East 
London your research must be conducted in accordance with NHS 
regulations and any requirements specified as part of your NHS R&D ethical 
approval. 
 
Please confirm that you will conduct your study in accordance with the 
consent given by the Trust Research Ethics Committee by emailing 
researchethics@uel.ac.uk. 
 
Please ensure you retain this approval letter, as in the future you may 
be asked to provide proof of ethical approval. 
 
With the Committee’s best wishes for the success of this  
project. 
 
 
Yours sincerely, 
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Catherine Fieulleteau 
Research Integrity and Ethics Manager  
For and on behalf of  
Dr Lisa Mooney 
University Research Ethics Committee (UREC)  
Research Ethics 
Email: researchethics@uel.ac.uk 
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6.9 Appendix I: Consent Form for Camden Research Site 
 
Consent Form. Version 1.2 (1st September 2016) 
 
 
 
  
UNIVERSITY OF EAST LONDON 
 
Consent to participate in a research study  
 
How do working age adults with Type 2 Diabetes do on tests of Cognitive Ability? 
What is the cognitive ability of working age adults with Type 2 Diabetes? 
 
Please initial box:  
 
 
I confirm that I have read and understood the information sheet for this study and 
been given a copy of the information sheet to keep. 
 
I have been given the opportunity to ask questions, to which I have received  
satisfactory answers. 
 
I understand what is going to happen and what I am being asked to do. 
 
I understand that only the researcher, Katy Lucas, and her research supervisor  
will have access to the research data, to which I give my permission. 
 
I understand what will happen to the data once the research has been  
completed. 
 
I understand that my involvement in this study is voluntary and that I may  
withdraw at any time if I wish to do so, and this will not affect the standard of  
care I continue to receive by the service.  
 
I hereby fully and freely agree to take part in the research, which has been  
fully explained to me. 
 
 
Participant’s Name (BLOCK CAPITALS) ……………………………………………………. 
 
 
Participant’s Signature ………………….……………………………………………………….. 
 
 
Researcher’s Name (BLOCK CAPITALS) …………………………………………………….. 
 
 
Researcher’s Signature ….……………………………………………………………………… 
 
Date: …………………….. 
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6.10 Appendix J: Interview Protocol 
 
Protocol Version 1.1 (4th August 2016) IRAS 203389 
 
UNIVERSITY OF EAST LONDON 
School of Psychology 
Stratford Campus 
Water Lane 
London E15 4LZ 
 
 
Schedule and Procedural Information for Administered Questionnaires 
 
Tests will be administered in the same order and a break will be added at the 
same time (or whenever the participant requires) to the schedule. 
 
Introductions  
Check preferred name, explain confidentiality, consent and right to withdraw at 
any point. Confirm length of assessment.   
 
Rapport Building 
Journey to session, and how they feel physically.  
 
Brief Demographic Interview  
Check DOB, education and occupational history, when they left school, highest 
level of education, left or right handedness.   
 
Medical History  
Diabetes-Related Health Indicators: duration of diabetes, hypertension status, 
CVD status, stroke status, other relevant information.  
Cognitive Event History Head injury, stroke, and muscular sclerosis  
 
Testing:  
 
1.  Test Of Premorbid Functioning (TOPF) – this test is to estimate a level of 
cognitive and memory functioning before the onset of illness, in this case 
diabetes.   This involves pronouncing words that have atypical grapheme to 
phoneme translations, and accordingly success depends on prior knowledge of 
the items. Participants will be required to pronounce as many words as they can 
from a displayed list of words of increasing difficulty. 
 
2.  WAIS Block Design 
In this test of perception and construction, the participant has a limited time in 
which to view a design and use red-and-white blocks to recreate the design. 
 
3.  WAIS Similarities 
In this test of verbal reasoning, the participant is presented with two words and is 
required to say how they are alike (related). 
 
4.  WAIS Digit Span 
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This test of short-term stores and working memory has 3 components.  For digit 
span forwards, the participant is read a sequence of numbers and recalls the 
numbers in the same order. For Digit Span Backwards, the participant is read a 
sequence of numbers and recalls the numbers in reverse order. For Digit Span 
Sequencing, the participant is read a sequence of numbers and recalls the 
numbers in ascending numerical order. 
 
5.  WAIS Digit Symbol Coding 
A test of processing speed:  the participant is required to use a key/legend and 
copies symbols that are paired with numbers within a specific time limit. 
 
6.  WMS Visual reproduction I 
This test assesses memory for nonverbal stimuli. A series of five designs is 
shown, one at a time, for 10 seconds each. After each design is presented, the 
examinee is asked to draw the design from memory. 
 
7.  WMS Logical Memory I 
This assesses narrative memory under a free recall condition. Two short stories 
are orally presented. The examinee is asked to retell each story from memory 
immediately after hearing it. 
 
9.  Comfort Break Offered 
 
10.  DKEFS Verbal Fluency 
This is a measure of mental set and shift (flexibility).  The participant is asked 
within a time limit to give (a) words that begin with a specific letter of the 
alphabet, then (b) items from specific categories (e.g., animals) and then (c) to 
switch between two categories (e.g., animals and boys names). 
 
11. DKEFS Trail Making Test 
This is a measure of sequencing and alternation.  The participant is asked to (a) 
join up circles on a printed page (a) in number order (i.e., 1-2-3) and then (b) in 
alphabetical order (i.e., A-B-C) and then (c) to switch between numbers and 
letters but sticking to order (i.e., 1-A-2-B etc.). 
 
12.  DKEFS Colour-Word Inference 
This is a measure of the ability to inhibit a well-learned response (reading).  It has 
four conditions (a) simple colour naming (b) colour-word reading (c) ink- colour 
naming (inhibition, in which colour words are printed in incongruent inks) and (d) 
switching between naming the ink versus reading the word. 
 
13.  Beck Depression Inventory (BDI) 
The BDI is a 21-question multiple-choice self-report inventory measuring low 
mood and symptoms of depression, occurring over the last week.  
 
14.  Beck Anxiety Inventory  
The BAI is a 21-questios multiple-choice self-report inventory measuring the 
symptoms of anxiety, occurring over the last week. 
 
15. WMS Visual Reproduction II 
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This assesses long term visual-spatial memory free recall.  The examinee is 
asked to draw the designs shown during the immediate recall condition from 
memory in any order. 
 
16. WMS Logical Memory II 
This assesses long-term narrative memory with free recall and recognition tasks. 
The examinee is asked to retell both stories from the immediate condition. Then 
the examinee is asked yes/no questions about both stories.  
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6.11 Appendix K: Participant Debrief Sheet 
 
Debrief Sheet and Sources of Information and Support: Version 
1.2 (20th September 2016) IRAS 203389 
 
UNIVERSITY  
OF EAST LONDON 
School of Psychology 
Stratford Campus 
Water Lane 
London E15 4LZ 
 
PARTICIPANT DEBRIEF SHEET 
 
Project Title:  Cognitive function & Type 2 Diabetes: A Study Using Working Age 
Adults 
 
Principal Investigator(s):  Katy Lucas 
     E-mail: u1438310@uel.ac.uk 
     Telephone: 0208 223 4174 
 
Thank you for your participation in the study 
This debrief sheet is to note our appreciation for your time and effort for taking 
part in the study today. We have reiterated a few key points of information but if 
you have any questions that are not covered below, please do not hesitate to 
ask. 
 
What will happen to the results of the research study? 
The results of the study will be written up as a doctoral thesis and submitted for 
publication in a journal.  In all written material of this study your identity will 
remain anonymous.  The data will be stored for three years, following which time 
it will be shredded and disposed of. 
 
Who should I contact if I need additional support? 
Whilst we hope that we have provided sufficient information and support, should 
you want more support or if you experience any distress or concern as a result of 
participating in your research, we have provided information about who to 
contact: 
 
Diabetes Service 
As the Diabetes Service in Camden referred you, you can contact the service 
with questions about your condition. The clinicians in the service are aware of the 
research and so are receptive to questions following your participation. Please 
contact Katy Lucas for more information 
 
Psychology Service 
There is a psychology service attached to the diabetes service, and clinicians in 
the Camden Diabetes service can make referrals to psychology at your request. 
Please contact Katy Lucas for more information.  
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Diabetes UK 
Diabetes UK is the leading UK charity that cares for, connects with and 
campaigns on behalf of all people affected by diabetes. They have a careline 
open Monday to Friday for people with diabetes, their friends, family and carers 
0345 123 2399. They also have a website https://www.diabetes.org.uk/, which also 
details their local support groups amongst other support. 
https://www.diabetes.org.uk/How_we_help/Local_support_groups/  
 
In an emergency, please contact your GP or go to your nearest A+E 
department 
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6.12 Appendix L: Blank Record Form 
Cognitive Function in Young Adults with T2DM 
Researcher: Katy LUCAS.  Email: u1438310@uel.ac.uk 
v1.2 (1st September 2016) IRAS: 203389 
 
Record Form 
 
Demographic & Clinical Details 
ID:    Exam by:  
DoB:    Exam Date:  
Age:    Exam Location:  
Primary Language:    Gender:  
Years Education:    Handedness:  
 
Medical History 
Head Injury:  Stroke:  MS:  
Details/Other:  
Relevant Medical Values  
Duration of 
T2DM:  LDL: %/2 mmol 
Recent Hba1C: %/mol  HDL: %/mmol 
Chol – Total: %/mmol  TRI: %/mmol 
Inclusion/Exclusion Check 
History of high blood pressure:  History of cardiovascular disease: 
History of severe mental illness:  History of colour blindness:  
 
Domain Test Raw Scaled %ile Label 
Optimal Ability TOPF-UK     
Verbal Attention 
Digits Forward     
Digits Backward     
Digits Sequencing     
Digit Span Overall     
Processing Speed 
Digit-Symbol Coding     
Colour Naming     
Colour Word Reading     
Visual Scanning     
Number Sequencing     
Letter Sequencing     
Executive Function: 
Letter Fluency     
Category Fluency     
Switch Output     
Switch Accuracy     
Inhibition     
Inhibition Switching     
Number Letter 
Switching     
Learning & Memory: 
Verbal 
Story Immediate     
Story Delayed Recall     
Story Recognition     
Learning & Memory: 
Visual 
Visual Immediate     
Visual Delayed Recall     
Visual Recognition     
Verbal & Visuo-spatial Similarities     Block Design     
Mood Beck Depression     Beck Anxiety     
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6.13 Appendix M - Conversion Table for Scaled Scores 
 
Scaled Standard T-score %ile Label %ile Range 
 
19 145 80 99.9 Very- >98th 
18 140 77 99.6 Superior  
17 135 73 99.0   
16 130 70 97.7 Superior 91-98th 
15 125 67 95.2   
14 120 63 90.9   
13 115 60 84.1 High 75-90th 
12 110 57 74.8 Average  
11 105 53 63.1  50-74th 
10 100 50 50.0 Average  
9 95 47 36.9  25-49th 
8 90 43 25.3   
7 85 40 15.9 Low- 10-24th 
6 80 37 9.1 Average  
5 75 33 4.8 Below- 2-9th 
4 70 30 2.3 Normal  
3 65 27 1.0 Impaired <2nd 
2 60 23 0.4   
1 55 20 0.1   
 
 
  
